{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "ASI_ONE_KEY = os.getenv(\"ASI_ONE_KEY\")\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")\n",
    "MODEL = \"asi1-mini\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Pre-procesare ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Downloaded pdfs/doc_0.pdf\n",
      "Downloaded pdfs/doc_1.pdf\n",
      "Downloaded pdfs/doc_2.pdf\n",
      "Downloaded pdfs/doc_3.pdf\n",
      "Downloaded pdfs/doc_4.pdf\n",
      "Downloaded pdfs/doc_5.pdf\n",
      "Downloaded pdfs/doc_6.pdf\n",
      "Downloaded pdfs/doc_7.pdf\n",
      "Downloaded pdfs/doc_8.pdf\n",
      "Downloaded pdfs/doc_9.pdf\n",
      "Downloaded pdfs/doc_10.pdf\n",
      "Downloaded pdfs/doc_11.pdf\n",
      "Downloaded pdfs/doc_12.pdf\n",
      "Downloaded pdfs/doc_13.pdf\n",
      "Downloaded pdfs/doc_14.pdf\n",
      "Downloaded pdfs/doc_15.pdf\n",
      "Downloaded pdfs/doc_16.pdf\n",
      "Downloaded pdfs/doc_17.pdf\n",
      "Downloaded pdfs/doc_18.pdf\n",
      "Downloaded pdfs/doc_19.pdf\n",
      "Downloaded pdfs/doc_20.pdf\n",
      "Downloaded pdfs/doc_21.pdf\n",
      "Downloaded pdfs/doc_22.pdf\n",
      "Downloaded pdfs/doc_23.pdf\n",
      "Downloaded pdfs/doc_24.pdf\n",
      "Downloaded pdfs/doc_25.pdf\n",
      "Downloaded pdfs/doc_26.pdf\n",
      "Downloaded pdfs/doc_27.pdf\n",
      "Downloaded pdfs/doc_28.pdf\n",
      "Downloaded pdfs/doc_29.pdf\n",
      "Downloaded pdfs/doc_30.pdf\n",
      "Downloaded pdfs/doc_31.pdf\n",
      "Downloaded pdfs/doc_32.pdf\n",
      "Downloaded pdfs/doc_33.pdf\n",
      "Downloaded pdfs/doc_34.pdf\n",
      "Downloaded pdfs/doc_35.pdf\n",
      "Downloaded pdfs/doc_36.pdf\n",
      "Downloaded pdfs/doc_37.pdf\n",
      "Downloaded pdfs/doc_38.pdf\n",
      "Downloaded pdfs/doc_39.pdf\n",
      "Downloaded pdfs/doc_40.pdf\n",
      "Downloaded pdfs/doc_41.pdf\n",
      "Downloaded pdfs/doc_42.pdf\n",
      "Downloaded pdfs/doc_43.pdf\n",
      "Downloaded pdfs/doc_44.pdf\n",
      "Downloaded pdfs/doc_45.pdf\n",
      "Downloaded pdfs/doc_46.pdf\n",
      "Downloaded pdfs/doc_47.pdf\n",
      "Downloaded pdfs/doc_48.pdf\n",
      "Downloaded pdfs/doc_49.pdf\n",
      "Downloaded pdfs/doc_50.pdf\n",
      "Downloaded pdfs/doc_51.pdf\n",
      "Downloaded pdfs/doc_52.pdf\n",
      "Downloaded pdfs/doc_53.pdf\n",
      "Downloaded pdfs/doc_54.pdf\n",
      "Downloaded pdfs/doc_55.pdf\n",
      "Downloaded pdfs/doc_56.pdf\n",
      "Downloaded pdfs/doc_57.pdf\n",
      "Downloaded pdfs/doc_58.pdf\n",
      "Downloaded pdfs/doc_59.pdf\n",
      "Downloaded pdfs/doc_60.pdf\n",
      "Downloaded pdfs/doc_61.pdf\n",
      "Downloaded pdfs/doc_62.pdf\n",
      "Downloaded pdfs/doc_63.pdf\n",
      "Downloaded pdfs/doc_64.pdf\n",
      "Downloaded pdfs/doc_65.pdf\n",
      "Downloaded pdfs/doc_66.pdf\n",
      "Downloaded pdfs/doc_67.pdf\n",
      "Downloaded pdfs/doc_68.pdf\n",
      "Downloaded pdfs/doc_69.pdf\n",
      "Downloaded pdfs/doc_70.pdf\n",
      "Downloaded pdfs/doc_71.pdf\n",
      "Downloaded pdfs/doc_72.pdf\n",
      "Downloaded pdfs/doc_73.pdf\n",
      "Downloaded pdfs/doc_74.pdf\n",
      "Downloaded pdfs/doc_75.pdf\n",
      "Downloaded pdfs/doc_76.pdf\n",
      "Downloaded pdfs/doc_77.pdf\n",
      "Downloaded pdfs/doc_78.pdf\n",
      "Downloaded pdfs/doc_79.pdf\n",
      "Downloaded pdfs/doc_80.pdf\n",
      "Downloaded pdfs/doc_81.pdf\n",
      "Downloaded pdfs/doc_82.pdf\n",
      "Downloaded pdfs/doc_83.pdf\n",
      "Downloaded pdfs/doc_84.pdf\n",
      "Downloaded pdfs/doc_85.pdf\n",
      "Downloaded pdfs/doc_86.pdf\n",
      "Downloaded pdfs/doc_87.pdf\n",
      "Downloaded pdfs/doc_88.pdf\n",
      "Downloaded pdfs/doc_89.pdf\n",
      "Downloaded pdfs/doc_90.pdf\n",
      "Downloaded pdfs/doc_91.pdf\n",
      "Downloaded pdfs/doc_92.pdf\n",
      "Downloaded pdfs/doc_93.pdf\n",
      "Downloaded pdfs/doc_94.pdf\n",
      "Downloaded pdfs/doc_95.pdf\n",
      "Downloaded pdfs/doc_96.pdf\n",
      "Downloaded pdfs/doc_97.pdf\n",
      "Downloaded pdfs/doc_98.pdf\n",
      "Downloaded pdfs/doc_99.pdf\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "import os\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "\n",
    "\n",
    "os.makedirs(\"pdfs\", exist_ok=True)\n",
    "\n",
    "df = pd.read_csv(\"dataset.csv\")\n",
    "links = df['link'].tolist()\n",
    "\n",
    "pdf_files = []\n",
    "\n",
    "for i, link in enumerate(links):\n",
    "    filename = f\"pdfs/doc_{i}.pdf\"\n",
    "    try:\n",
    "        r = requests.get(link)\n",
    "        if r.ok:\n",
    "            with open(filename, \"wb\") as f:\n",
    "                f.write(r.content)\n",
    "            pdf_files.append(filename)\n",
    "            print(f\"Downloaded {filename}\")\n",
    "        else:\n",
    "            print(f\"Failed to download {link}\")\n",
    "    except Exception as e:\n",
    "        print(f\"Error downloading {link}: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Parsed pdfs/doc_0.pdf with 6 chunks.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Exception ignored in: <bound method IPythonKernel._clean_thread_parent_frames of <ipykernel.ipkernel.IPythonKernel object at 0x70419b155640>>\n",
      "Traceback (most recent call last):\n",
      "  File \"/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/ipykernel/ipkernel.py\", line 775, in _clean_thread_parent_frames\n",
      "    def _clean_thread_parent_frames(\n",
      "\n",
      "KeyboardInterrupt: \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Parsed pdfs/doc_1.pdf with 22 chunks.\n",
      "Parsed pdfs/doc_2.pdf with 3 chunks.\n",
      "Parsed pdfs/doc_3.pdf with 31 chunks.\n",
      "Parsed pdfs/doc_4.pdf with 30 chunks.\n",
      "Parsed pdfs/doc_5.pdf with 21 chunks.\n",
      "Parsed pdfs/doc_6.pdf with 20 chunks.\n",
      "Parsed pdfs/doc_7.pdf with 6 chunks.\n",
      "Parsed pdfs/doc_8.pdf with 3 chunks.\n",
      "Parsed pdfs/doc_9.pdf with 26 chunks.\n",
      "Parsed pdfs/doc_10.pdf with 20 chunks.\n",
      "Parsed pdfs/doc_11.pdf with 5 chunks.\n",
      "Parsed pdfs/doc_12.pdf with 5 chunks.\n",
      "Parsed pdfs/doc_13.pdf with 7 chunks.\n",
      "Parsed pdfs/doc_14.pdf with 11 chunks.\n",
      "Parsed pdfs/doc_15.pdf with 5 chunks.\n",
      "Parsed pdfs/doc_16.pdf with 3 chunks.\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mKeyboardInterrupt\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[19]\u001b[39m\u001b[32m, line 6\u001b[39m\n\u001b[32m      4\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m      5\u001b[39m     loader = PyPDFLoader(filepath)\n\u001b[32m----> \u001b[39m\u001b[32m6\u001b[39m     docs = \u001b[43mloader\u001b[49m\u001b[43m.\u001b[49m\u001b[43mload\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m      7\u001b[39m     full_document.extend(docs)\n\u001b[32m      8\u001b[39m     \u001b[38;5;28mprint\u001b[39m(\u001b[33mf\u001b[39m\u001b[33m\"\u001b[39m\u001b[33mParsed \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mfilepath\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m with \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mlen\u001b[39m(docs)\u001b[38;5;132;01m}\u001b[39;00m\u001b[33m chunks.\u001b[39m\u001b[33m\"\u001b[39m)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/langchain_core/document_loaders/base.py:32\u001b[39m, in \u001b[36mBaseLoader.load\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m     30\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mload\u001b[39m(\u001b[38;5;28mself\u001b[39m) -> \u001b[38;5;28mlist\u001b[39m[Document]:\n\u001b[32m     31\u001b[39m \u001b[38;5;250m    \u001b[39m\u001b[33;03m\"\"\"Load data into Document objects.\"\"\"\u001b[39;00m\n\u001b[32m---> \u001b[39m\u001b[32m32\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mlist\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mlazy_load\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/langchain_community/document_loaders/pdf.py:305\u001b[39m, in \u001b[36mPyPDFLoader.lazy_load\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    303\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m    304\u001b[39m     blob = Blob.from_path(\u001b[38;5;28mself\u001b[39m.file_path)\n\u001b[32m--> \u001b[39m\u001b[32m305\u001b[39m \u001b[38;5;28;01myield from\u001b[39;00m \u001b[38;5;28mself\u001b[39m.parser.lazy_parse(blob)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/langchain_community/document_loaders/parsers/pdf.py:396\u001b[39m, in \u001b[36mPyPDFParser.lazy_parse\u001b[39m\u001b[34m(self, blob)\u001b[39m\n\u001b[32m    394\u001b[39m single_texts = []\n\u001b[32m    395\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m page_number, page \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(pdf_reader.pages):\n\u001b[32m--> \u001b[39m\u001b[32m396\u001b[39m     text_from_page = \u001b[43m_extract_text_from_page\u001b[49m\u001b[43m(\u001b[49m\u001b[43mpage\u001b[49m\u001b[43m=\u001b[49m\u001b[43mpage\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    397\u001b[39m     images_from_page = \u001b[38;5;28mself\u001b[39m.extract_images_from_page(page)\n\u001b[32m    398\u001b[39m     all_text = _merge_text_and_extras(\n\u001b[32m    399\u001b[39m         [images_from_page], text_from_page\n\u001b[32m    400\u001b[39m     ).strip()\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/langchain_community/document_loaders/parsers/pdf.py:378\u001b[39m, in \u001b[36mPyPDFParser.lazy_parse.<locals>._extract_text_from_page\u001b[39m\u001b[34m(page)\u001b[39m\n\u001b[32m    376\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m page.extract_text()\n\u001b[32m    377\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m378\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mpage\u001b[49m\u001b[43m.\u001b[49m\u001b[43mextract_text\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    379\u001b[39m \u001b[43m        \u001b[49m\u001b[43mextraction_mode\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mextraction_mode\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    380\u001b[39m \u001b[43m        \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mextraction_kwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    381\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/pypdf/_page.py:2350\u001b[39m, in \u001b[36mPageObject.extract_text\u001b[39m\u001b[34m(self, orientations, space_width, visitor_operand_before, visitor_operand_after, visitor_text, extraction_mode, *args, **kwargs)\u001b[39m\n\u001b[32m   2347\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(orientations, \u001b[38;5;28mint\u001b[39m):\n\u001b[32m   2348\u001b[39m     orientations = (orientations,)\n\u001b[32m-> \u001b[39m\u001b[32m2350\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_extract_text\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   2351\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[32m   2352\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mpdf\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2353\u001b[39m \u001b[43m    \u001b[49m\u001b[43morientations\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2354\u001b[39m \u001b[43m    \u001b[49m\u001b[43mspace_width\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2355\u001b[39m \u001b[43m    \u001b[49m\u001b[43mPG\u001b[49m\u001b[43m.\u001b[49m\u001b[43mCONTENTS\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2356\u001b[39m \u001b[43m    \u001b[49m\u001b[43mvisitor_operand_before\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2357\u001b[39m \u001b[43m    \u001b[49m\u001b[43mvisitor_operand_after\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2358\u001b[39m \u001b[43m    \u001b[49m\u001b[43mvisitor_text\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2359\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/pypdf/_page.py:2120\u001b[39m, in \u001b[36mPageObject._extract_text\u001b[39m\u001b[34m(self, obj, pdf, orientations, space_width, content_key, visitor_operand_before, visitor_operand_after, visitor_text)\u001b[39m\n\u001b[32m   2118\u001b[39m         memo_tm = tm_matrix.copy()\n\u001b[32m   2119\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m-> \u001b[39m\u001b[32m2120\u001b[39m     \u001b[43mprocess_operation\u001b[49m\u001b[43m(\u001b[49m\u001b[43moperator\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43moperands\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   2121\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m visitor_operand_after \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m   2122\u001b[39m     visitor_operand_after(operator, operands, cm_matrix, tm_matrix)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/disi/.venv/lib/python3.12/site-packages/pypdf/_page.py:1874\u001b[39m, in \u001b[36mPageObject._extract_text.<locals>.process_operation\u001b[39m\u001b[34m(operator, operands)\u001b[39m\n\u001b[32m   1871\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mcompute_str_widths\u001b[39m(str_widths: \u001b[38;5;28mfloat\u001b[39m) -> \u001b[38;5;28mfloat\u001b[39m:\n\u001b[32m   1872\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m str_widths / \u001b[32m1000\u001b[39m\n\u001b[32m-> \u001b[39m\u001b[32m1874\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mprocess_operation\u001b[39m(operator: \u001b[38;5;28mbytes\u001b[39m, operands: List[Any]) -> \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m   1875\u001b[39m     \u001b[38;5;28;01mnonlocal\u001b[39;00m cm_matrix, tm_matrix, cm_stack, cm_prev, tm_prev, memo_cm, memo_tm\n\u001b[32m   1876\u001b[39m     \u001b[38;5;28;01mnonlocal\u001b[39;00m char_scale, space_scale, _space_width, TL, font_size, cmap\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m: "
     ]
    }
   ],
   "source": [
    "full_document = []\n",
    "\n",
    "for filepath in pdf_files:\n",
    "    try:\n",
    "        loader = PyPDFLoader(filepath)\n",
    "        docs = loader.load()\n",
    "        full_document.extend(docs)\n",
    "        print(f\"Parsed {filepath} with {len(docs)} chunks.\")\n",
    "    except Exception as e:\n",
    "        print(f\"Error parsing {filepath}: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "page_content='12 HOUR NASAL DECONGESTANT- pseudoephedrine hydrochloride tablet, film\n",
      "coated \n",
      " \n",
      "CARDINAL HEALTH\n",
      "----------\n",
      "Pseudoephedrine hydrochloride\n",
      "Drug Facts\n",
      "Active ingredient (in each tablet)\n",
      "Pseudoephedrine HCl, USP 120 mg\n",
      "Purpose\n",
      "Nasal decongestant\n",
      "Uses\n",
      "temporarily relieves nasal congestion due to the common cold, hay fever or other\n",
      "upper respiratory allergies\n",
      "temporarily relieves sinus congestion and pressure\n",
      "Warnings\n",
      "Do not use\n",
      " if you are now taking a prescription monoamine oxidase inhibitor (MAOI)\n",
      "(certain drugs for depression, psychiatric or emotional conditions, or Parkinson's\n",
      "disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your\n",
      "prescription drug contains an MAOI, ask a doctor or pharmacist before taking this\n",
      "product.\n",
      "Ask a doctor before use if you have\n",
      "heart disease\n",
      "high blood pressure\n",
      "thyroid disease\n",
      "diabetes\n",
      "trouble urinating due to an enlarged prostate gland\n",
      "When using this product do not exceed recommended dosage\n",
      "Stop use and ask a doctor if\n",
      "nervousness, dizziness, or sleeplessness occur\n",
      "symptoms do not improve within 7 days or occur with a fever\n",
      "If pregnant or breast-feeding,\n",
      " ask a health professional before use.\n",
      "Keep out of reach of children.\n",
      " In case of overdose, get medical help or contact a\n",
      "Poison Control Center right away. (1-800-222-1222)' metadata={'producer': 'wkhtmltopdf', 'creator': '', 'creationdate': '2024-05-23T18:18:46-04:00', 'title': 'Pseudoephedrine hydrochloride', 'source': 'pdfs/doc_0.pdf', 'total_pages': 6, 'page': 0, 'page_label': '1'}\n"
     ]
    }
   ],
   "source": [
    "print(full_document[0])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Split ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "text_splitter = RecursiveCharacterTextSplitter.from_tiktoken_encoder(\n",
    "    chunk_size=300, \n",
    "    chunk_overlap=50)\n",
    "\n",
    "# Make splits\n",
    "splits = text_splitter.split_documents(full_document)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Index with Retrieval ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Index\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain_community.vectorstores import Chroma\n",
    "\n",
    "vectorstore = Chroma.from_documents(documents=splits, \n",
    "                                    embedding=OpenAIEmbeddings(model=\"text-embedding-3-small\"))\n",
    "\n",
    "retriever = vectorstore.as_retriever(search_kwargs={\"k\": 3})\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Model ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def call_asi_one(prompt):\n",
    "    if hasattr(prompt, \"to_string\"):\n",
    "        prompt = prompt.to_string()  # Convert PromptValue to str\n",
    "\n",
    "    url = \"https://api.asi1.ai/v1/chat/completions\"\n",
    "    headers = {\n",
    "        'Content-Type': 'application/json',\n",
    "        'Authorization': f'Bearer {ASI_ONE_KEY}'\n",
    "    }\n",
    "    payload = {\n",
    "        \"model\": MODEL,\n",
    "        \"messages\": [{\"role\": \"user\", \"content\": prompt}],\n",
    "        \"temperature\": 0.2,\n",
    "        \"max_tokens\": 1000\n",
    "    }\n",
    "    response = requests.post(url, headers=headers, json=payload)\n",
    "    return response.json().get(\"choices\", [{}])[0].get(\"message\", {}).get(\"content\", \"No response\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# LLM\n",
    "llm = call_asi_one"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Multi Query ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "# Prompt\n",
    "template = \"\"\"You are an AI language model assistant. Your task is to generate five \n",
    "different versions of the given user question to retrieve relevant documents from a vector \n",
    "database. By generating multiple perspectives on the user question, your goal is to help\n",
    "the user overcome some of the limitations of the distance-based similarity search. \n",
    "Provide these alternative questions separated by newlines. Original question: {question}\n",
    "\"\"\"\n",
    "\n",
    "prompt_perspectives = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "\n",
    "generate_queries = (\n",
    "    prompt_perspectives \n",
    "    | llm \n",
    "    | StrOutputParser() \n",
    "    | (lambda x: x.split(\"\\n\"))\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.load import dumps, loads\n",
    "\n",
    "def get_unique_union(documents: list[list]):\n",
    "    \"\"\" Unique union of retrieved docs \"\"\"\n",
    "    # Flatten list of lists, and convert each Document to string\n",
    "    flattened_docs = [dumps(doc) for sublist in documents for doc in sublist]\n",
    "    # Get unique documents\n",
    "    unique_docs = list(set(flattened_docs))\n",
    "    # Return\n",
    "    return [loads(doc) for doc in unique_docs]\n",
    "\n",
    "# Retrieve\n",
    "\n",
    "retrieval_chain = generate_queries | retriever.map() | get_unique_union\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "from operator import itemgetter\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "# RAG\n",
    "template = \"\"\"\n",
    "Answer the question only based on the context below use only the given knowledge from the context do not invent or add details that you were treained. \n",
    "If you dont know the answer say that you dont know.\n",
    " \n",
    "Context: {context}\n",
    "\n",
    "Question: {question}\n",
    "\"\"\"\n",
    "prompt = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "\n",
    "chain = (\n",
    "    {\"context\": retrieval_chain, \n",
    "     \"question\": itemgetter(\"question\")} \n",
    "    | prompt\n",
    "    | llm\n",
    "    | StrOutputParser()\n",
    ")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_18318/3938202853.py:10: LangChainBetaWarning: The function `loads` is in beta. It is actively being worked on, so the API may change.\n",
      "  return [loads(doc) for doc in unique_docs]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "\"The context provided describes NASAL DECONGESTANT as a type of medication containing **Pseudoephedrine HCl, USP 120 mg** as the active ingredient. Its purpose is to temporarily relieve nasal congestion due to:  \\n- The common cold  \\n- Hay fever or other upper respiratory allergies  \\n- Sinus congestion and pressure  \\n\\n**Warnings include:**  \\n- Not using it with MAO inhibitors (for depression, Parkinson's, etc.) or within 2 weeks of stopping them.  \\n- Consulting a doctor before use if the user has heart disease, high blood pressure, thyroid disease, diabetes, or an enlarged prostate gland.  \\n\\nNo additional details beyond this context are available.\""
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chain.invoke({\"question\":\"What is NASAL DECONGESTANT?\"})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### RAG-Fusion ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "\n",
    "# RAG-Fusion: Related\n",
    "template = \"\"\"You are a helpful assistant that generates multiple search queries based on a single input query. \\n\n",
    "Generate multiple search queries related to: {question} \\n\n",
    "Output (4 queries):\"\"\"\n",
    "prompt_rag_fusion = ChatPromptTemplate.from_template(template)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "\n",
    "generate_queries = (\n",
    "    prompt_rag_fusion \n",
    "    | llm\n",
    "    | StrOutputParser() \n",
    "    | (lambda x: x.split(\"\\n\"))\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.load import dumps, loads\n",
    "\n",
    "def reciprocal_rank_fusion(results: list[list], k=60):\n",
    "    \"\"\" Reciprocal_rank_fusion that takes multiple lists of ranked documents \n",
    "        and an optional parameter k used in the RRF formula \"\"\"\n",
    "    \n",
    "    # Initialize a dictionary to hold fused scores for each unique document\n",
    "    fused_scores = {}\n",
    "\n",
    "    # Iterate through each list of ranked documents\n",
    "    for docs in results:\n",
    "        # Iterate through each document in the list, with its rank (position in the list)\n",
    "        for rank, doc in enumerate(docs):\n",
    "            # Convert the document to a string format to use as a key (assumes documents can be serialized to JSON)\n",
    "            doc_str = dumps(doc)\n",
    "            # If the document is not yet in the fused_scores dictionary, add it with an initial score of 0\n",
    "            if doc_str not in fused_scores:\n",
    "                fused_scores[doc_str] = 0\n",
    "            # Retrieve the current score of the document, if any\n",
    "            previous_score = fused_scores[doc_str]\n",
    "            # Update the score of the document using the RRF formula: 1 / (rank + k)\n",
    "            fused_scores[doc_str] += 1 / (rank + k)\n",
    "\n",
    "    # Sort the documents based on their fused scores in descending order to get the final reranked results\n",
    "    reranked_results = [\n",
    "        (loads(doc), score)\n",
    "        for doc, score in sorted(fused_scores.items(), key=lambda x: x[1], reverse=True)\n",
    "    ]\n",
    "\n",
    "    # Return the reranked results as a list of tuples, each containing the document and its fused score\n",
    "    return reranked_results\n",
    "\n",
    "retrieval_chain_rag_fusion = generate_queries | retriever.map() | reciprocal_rank_fusion\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "from langchain_core.runnables import RunnablePassthrough\n",
    "\n",
    "# RAG\n",
    "template = \"\"\"Answer the following question based on this context:\n",
    "\n",
    "{context}\n",
    "\n",
    "Question: {question}\n",
    "\"\"\"\n",
    "\n",
    "prompt = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "final_rag_chain = (\n",
    "    {\"context\": retrieval_chain_rag_fusion, \n",
    "     \"question\": itemgetter(\"question\")} \n",
    "    | prompt\n",
    "    | llm\n",
    "    | StrOutputParser()\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'ATRIPLA™ is a **three-drug fixed-dose combination** medication used in the treatment of **HIV-1 infection**. Here’s a concise breakdown of its key features:  \\n\\n### **Active Ingredients:**  \\n- **600 mg efavirenz (EFV)** (a non-nucleoside reverse transcriptase inhibitor, NNRTI)  \\n- **200 mg emtricitabine (FTC)** (a nucleoside reverse transcriptase inhibitor, NRTI)  \\n- **300 mg tenofovir disoproxil fumarate (TDF)** (an NRTI)  \\n\\n### **Recommended Use:**  \\n- **Dosage:** One tablet **once daily**, taken **on an empty stomach** (or at bedtime to reduce nervous system side effects).  \\n- **Patient Eligibility:** Adults and pediatric patients **weighing ≥40 kg**.  \\n\\n### **Contraindications & Warnings:**  \\n- **Not recommended** for patients with:  \\n  - **Moderate-to-severe renal impairment** (creatinine clearance <50 mL/min).  \\n  - **Moderate-to-severe hepatic impairment** (Child-Pugh B or C).  \\n- **Avoid pregnancy** (risk of fetal harm); use effective contraception during and for **12 weeks after stopping** ATRIPLA.  \\n\\n### **Common Side Effects:**  \\n- Diarrhea, tiredness, dizziness, sleep problems, rash, nausea, headache, depression, abnormal dreams.  \\n\\n### **Storage:**  \\n- Keep **below 30°C (86°F)** in its original tightly closed container.  \\n\\nATRIPLA is **not interchangeable** with its individual components and requires adherence to **prescribed use only**. For full details, consult the prescribing information or a healthcare provider.  \\n\\nWould you like further clarification on any aspect?'"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_rag_chain.invoke({\"question\":\"What is Atripla?\"})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Decomposition ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "\n",
    "# Decomposition\n",
    "template = \"\"\"You are a helpful assistant that generates multiple sub-questions related to an input question. \\n\n",
    "The goal is to break down the input into a set of sub-problems / sub-questions that can be answers in isolation. \\n\n",
    "Generate multiple search queries related to: {question} \\n\n",
    "Output (3 queries):\"\"\"\n",
    "prompt_decomposition = ChatPromptTemplate.from_template(template)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"Here is the question you need to answer:\n",
    "\n",
    "\\n --- \\n {question} \\n --- \\n\n",
    "\n",
    "Here is any available background question + answer pairs:\n",
    "\n",
    "\\n --- \\n {q_a_pairs} \\n --- \\n\n",
    "\n",
    "Here is additional context relevant to the question: \n",
    "\n",
    "\\n --- \\n {context} \\n --- \\n\n",
    "\n",
    "Use the above context and any background question + answer pairs to answer the question: \\n {question}\n",
    "\"\"\"\n",
    "\n",
    "decomposition_prompt = ChatPromptTemplate.from_template(template)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "from operator import itemgetter\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "def format_qa_pair(question, answer):\n",
    "    \"\"\"Format Q and A pair\"\"\"\n",
    "    \n",
    "    formatted_string = \"\"\n",
    "    formatted_string += f\"Question: {question}\\nAnswer: {answer}\\n\\n\"\n",
    "    return formatted_string.strip()\n",
    "\n",
    "generate_queries_decomposition = (\n",
    "    prompt_decomposition | llm | StrOutputParser() | (lambda x: x.split(\"\\n\"))\n",
    ")\n",
    "def answer_fn2(question, history=None):\n",
    "    # Step 1: Generate sub-questions\n",
    "    questions = generate_queries_decomposition.invoke({\"question\": question})\n",
    "    \n",
    "    q_a_pairs = \"\"\n",
    "    \n",
    "    for q in questions:\n",
    "        rag_chain = (\n",
    "            {\n",
    "                \"context\": itemgetter(\"question\") | retriever,\n",
    "                \"question\": itemgetter(\"question\"),\n",
    "                \"q_a_pairs\": itemgetter(\"q_a_pairs\")\n",
    "            }\n",
    "            | decomposition_prompt\n",
    "            | llm\n",
    "            | StrOutputParser()\n",
    "        )\n",
    "        \n",
    "        answer = rag_chain.invoke({\"question\": q, \"q_a_pairs\": q_a_pairs})\n",
    "        q_a_pair = format_qa_pair(q, answer)\n",
    "        q_a_pairs = q_a_pairs + \"\\n---\\n\" + q_a_pair\n",
    "    \n",
    "    # Final full RAG answer based on original question\n",
    "    final_rag_chain = (\n",
    "        {\n",
    "            \"context\": itemgetter(\"question\") | retriever,\n",
    "            \"question\": itemgetter(\"question\"),\n",
    "            \"q_a_pairs\": itemgetter(\"q_a_pairs\")\n",
    "        }\n",
    "        | decomposition_prompt\n",
    "        | llm\n",
    "        | StrOutputParser()\n",
    "    )\n",
    "    \n",
    "    return final_rag_chain.invoke({\"question\": question, \"q_a_pairs\": q_a_pairs})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Step Back ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.prompts import ChatPromptTemplate, FewShotChatMessagePromptTemplate\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.runnables import RunnableLambda\n",
    "from operator import itemgetter\n",
    "\n",
    "# Few-shot examples\n",
    "examples = [\n",
    "    {\n",
    "        \"input\": \"Could the members of The Police perform lawful arrests?\",\n",
    "        \"output\": \"what can the members of The Police do?\",\n",
    "    },\n",
    "    {\n",
    "        \"input\": \"Jan Sindel’s was born in what country?\",\n",
    "        \"output\": \"what is Jan Sindel’s personal history?\",\n",
    "    },\n",
    "]\n",
    "\n",
    "# Prompt setup\n",
    "example_prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"human\", \"{input}\"),\n",
    "    (\"ai\", \"{output}\"),\n",
    "])\n",
    "few_shot_prompt = FewShotChatMessagePromptTemplate(\n",
    "    example_prompt=example_prompt,\n",
    "    examples=examples,\n",
    ")\n",
    "\n",
    "step_back_template = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are an expert at world knowledge. Your task is to step back and paraphrase a question to a more generic step-back question, which is easier to answer. Here are a few examples:\"),\n",
    "    few_shot_prompt,\n",
    "    (\"user\", \"{question}\"),\n",
    "])\n",
    "generate_queries_step_back = step_back_template | llm | StrOutputParser()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_prompt_template = \"\"\"You are an expert of world knowledge. I am going to ask you a question. Your response should be comprehensive and not contradicted with the following context if they are relevant. Otherwise, ignore them if they are not relevant.\n",
    "\n",
    "# {normal_context}\n",
    "# {step_back_context}\n",
    "\n",
    "# Original Question: {question}\n",
    "# Answer:\"\"\"\n",
    "response_prompt = ChatPromptTemplate.from_template(response_prompt_template)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_step_back(question):\n",
    "    step_back_chain = (\n",
    "        {\n",
    "            # Retrieve context using the normal question\n",
    "            \"normal_context\": RunnableLambda(lambda x: x[\"question\"]) | retriever,\n",
    "            # Retrieve context using the step-back question\n",
    "            \"step_back_context\": generate_queries_step_back | retriever,\n",
    "            # Pass original question\n",
    "            \"question\": lambda x: x[\"question\"],\n",
    "        }\n",
    "        | response_prompt\n",
    "        | llm\n",
    "        | StrOutputParser()\n",
    "    )\n",
    "    return step_back_chain.invoke({\"question\": question})\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Hyde ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "# Step 1: HyDE Prompt\n",
    "hyde_template = \"\"\"Please write a scientific paper passage to answer the question\n",
    "Question: {question}\n",
    "Passage:\"\"\"\n",
    "prompt_hyde = ChatPromptTemplate.from_template(hyde_template)\n",
    "\n",
    "generate_docs_for_retrieval = (\n",
    "    prompt_hyde | llm | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Step 2: Final RAG prompt\n",
    "rag_template = \"\"\"Answer the following question based on this context:\n",
    "\n",
    "{context}\n",
    "\n",
    "Question: {question}\n",
    "\"\"\"\n",
    "rag_prompt = ChatPromptTemplate.from_template(rag_template)\n",
    "\n",
    "final_rag_chain = (\n",
    "    rag_prompt\n",
    "    | llm\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_hyde(question):\n",
    "    # 1. Generate HyDE passage\n",
    "    pseudo_doc = generate_docs_for_retrieval.invoke({\"question\": question})\n",
    "    \n",
    "    # 2. Retrieve based on pseudo-doc\n",
    "    retrieved_docs = retriever.invoke(pseudo_doc)\n",
    "    \n",
    "    # 3. Answer with RAG\n",
    "    answer = final_rag_chain.invoke({\n",
    "        \"context\": retrieved_docs,\n",
    "        \"question\": question\n",
    "    })\n",
    "    \n",
    "    return answer"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Giskard ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>12 HOUR NASAL DECONGESTANT- pseudoephedrine hy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Directions\\nadults and children 12 years\\nand ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>COMPARE TO\\nSUDAFED\\n SINUS\\nCONGESTION 12 HOU...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12 HOUR NASAL DECONGESTANT  \\npseudoephedrine ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>absolute risk increase per mmHg is greater at ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>been studied. If treatment is to be discontinu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>dose of LOPRESSOR \\n[see \\nDosage and Administ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>5.\\n9\\n \\n  \\nPeripheral Vascular Disease\\nBet...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>Lopressor\\nPlacebo\\nHypotension (systolic BP &lt;...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 1 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 text\n",
       "0   12 HOUR NASAL DECONGESTANT- pseudoephedrine hy...\n",
       "1   Directions\\nadults and children 12 years\\nand ...\n",
       "2   COMPARE TO\\nSUDAFED\\n SINUS\\nCONGESTION 12 HOU...\n",
       "3                                                    \n",
       "4   12 HOUR NASAL DECONGESTANT  \\npseudoephedrine ...\n",
       "..                                                ...\n",
       "95  absolute risk increase per mmHg is greater at ...\n",
       "96  been studied. If treatment is to be discontinu...\n",
       "97  dose of LOPRESSOR \\n[see \\nDosage and Administ...\n",
       "98  5.\\n9\\n \\n  \\nPeripheral Vascular Disease\\nBet...\n",
       "99  Lopressor\\nPlacebo\\nHypotension (systolic BP <...\n",
       "\n",
       "[100 rows x 1 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "df = pd.DataFrame([d.page_content for d in full_document], columns=[\"text\"])\n",
    "\n",
    "df.head(100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import giskard\n",
    "\n",
    "\n",
    "giskard.llm.set_llm_model(\"gpt-3.5-turbo\")\n",
    "giskard.llm.set_embedding_model(\"text-embedding-3-small\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "from giskard.rag import KnowledgeBase\n",
    "\n",
    "knowledge_base = KnowledgeBase(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-16 10:04:54,620 pid:18318 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-16 10:06:25,446 pid:18318 MainThread giskard.rag  INFO     Found 54 topics in the knowledge base.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f261a0931d634f5f98e9c12371c9bff8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Generating questions:   0%|          | 0/110 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from giskard.rag import generate_testset\n",
    "\n",
    "testset = generate_testset(\n",
    "    knowledge_base,\n",
    "    num_questions=110,\n",
    "    agent_description=\"A chatbot answering questions about medicine drugs based on a given context\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question 1: What are the directions for taking Advil Gel Caplets?\n",
      "Reference answer: For Advil Gel Caplets, adults and children 12 years and over should take 1 gel caplet every 4 to 6 hours while symptoms persist. The smallest effective dose should be used. Do not exceed 6 gel caplets in 24 hours, unless directed by a doctor. Children under 12 years should ask a doctor before taking.\n",
      "Reference context:\n",
      "Document 8: vomit blood\n",
      "have bloody or black stools\n",
      "have stomach pain that does not get better\n",
      "you have symptoms of heart problems or stroke:\n",
      "chest pain\n",
      "trouble breathing\n",
      "weakness in one part or side of body\n",
      "slurred speech\n",
      "leg swelling\n",
      "pain gets worse or lasts more than 10 days\n",
      "fever gets worse or lasts more than 3 days\n",
      "redness or swelling is present in the painful area\n",
      "any new symptoms appear\n",
      "If pregnant or breast-feeding,\n",
      "ask a health professional before use. It is especially important not to use ibuprofen at 20\n",
      "weeks or later in pregnancy unless definitely directed to do so by a doctor because it\n",
      "may cause problems in the unborn child or complications during delivery.\n",
      "Keep out of reach of children.\n",
      "In case of overdose, get medical help or contact a Poison Control Center right away.\n",
      "Directions\n",
      "Advil Tablets\n",
      "do not take more than directed\n",
      "the smallest effective dose should be used\n",
      "adults and children 12 years and over: take 1 tablet every 4 to 6 hours while\n",
      "symptoms persist\n",
      "if pain or fever does not respond to 1 tablet, 2 tablets may be used\n",
      "do not exceed 6 tablets in 24 hours, unless directed by a doctor\n",
      "children under 12 years: ask a doctor\n",
      "Advil Caplets\n",
      "do not take more than directed\n",
      "the smallest effective dose should be used\n",
      "adults and children 12 years and over: take 1 caplet every 4 to 6 hours while\n",
      "symptoms persist\n",
      "if pain or fever does not respond to 1 caplet, 2 caplets may be used\n",
      "do not exceed 6 caplets in 24 hours, unless directed by a doctor\n",
      "children under 12 years: ask a doctor\n",
      "Advil Gel Caplets\n",
      "do not take more than directed\n",
      "the smallest effective dose should be used\n",
      "adults and children 12 years and over: take 1 gel caplet every 4 to 6 hours while\n",
      "symptoms persist\n",
      "------------------------------\n",
      "\n",
      "Question 2: What are the active ingredients in the atovaquone and proguanil hydrochloride tablet?\n",
      "Reference answer: The active ingredients in the atovaquone and proguanil hydrochloride tablet are Atovaquone (250 mg) and Proguanil Hydrochloride (100 mg).\n",
      "Reference context:\n",
      "Document 165: Mason, OH 45040 USA\n",
      "APH-PS:5PI\n",
      "Storage\n",
      "Store at 25oC (77oF); excursions permitted to 15o to 30oC (59o to 86oF) (see USP\n",
      "Controlled Room Temperature). Do not use if printed safety seal under cap is broken or\n",
      "missing.\n",
      "atovaquone and proguanil hydrochloride\n",
      "ATOVAQUONE AND PROGUANIL HCL  \n",
      "atovaquone and proguanil hydrochloride tablet, film coated\n",
      "Product Information\n",
      "Product Type\n",
      "HUMAN PRESCRIPTION\n",
      "DRUG\n",
      "Item Code\n",
      "(Source)\n",
      "NDC:50090-2980(NDC:66993-\n",
      "060)\n",
      "Route of Administration\n",
      "ORAL\n",
      "Active Ingredient/Active Moiety\n",
      "Ingredient Name\n",
      "Basis of Strength\n",
      "Strength\n",
      "ATOVAQUONE\n",
      " (UNII: Y883P1Z2LT) \n",
      "(ATOVAQUONE - UNII:Y883P1Z2LT)\n",
      "ATOVAQUONE\n",
      "250 mg\n",
      "PROGUANIL HYDROCHLORIDE\n",
      " (UNII: R71Y86M0WT) \n",
      "(PROGUANIL -\n",
      "UNII:S61K3P7B2V)\n",
      "PROGUANIL\n",
      "HYDROCHLORIDE\n",
      "100 mg\n",
      "Inactive Ingredients\n",
      "Ingredient Name\n",
      "Strength\n",
      "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED\n",
      " (UNII: 2165RE0K14)\n",
      " \n",
      "MAGNESIUM STEARATE\n",
      " (UNII: 70097M6I30)\n",
      "------------------------------\n",
      "\n",
      "Question 3: What steps should be taken if there is a suspicion of having consumed an excessive amount of NORVASC, and what specific actions should be avoided in such a situation?\n",
      "Reference answer: If you suspect you have taken too much NORVASC, you should call your doctor or Poison Control Center, or go to the nearest hospital emergency room right away.\n",
      "Reference context:\n",
      "Document 81: 4.\n",
      "How should I take NORVASC?\n",
      "1.\n",
      "2.\n",
      "3.\n",
      "4.\n",
      "5.\n",
      "6.\n",
      "What should I avoid while taking NORVASC?\n",
      "1.\n",
      "What are the possible side effects of NORVASC?\n",
      "NORVASC \n",
      "may cause the following side effects. \n",
      "Most side effects are mild or moderate:\n",
      "1.\n",
      "2.\n",
      "3.\n",
      "4.\n",
      "5.\n",
      "6.\n",
      "7.\n",
      "8.\n",
      "It is rare, but when you first start taking \n",
      "NORVASC\n",
      " or increase your dose, you may\n",
      "have a heart attack or your angina may get worse. \n",
      "If that happens, call your doctor\n",
      "right away or go directly to a hospital emergency room.\n",
      "Tell your doctor if you are concerned about any side effects you experience. These are\n",
      "not all the possible side effects of \n",
      "NORVASC\n",
      ". For a complete list, ask your doctor or\n",
      "pharmacist\n",
      ".\n",
      "How do I store NORVASC?\n",
      "Keep \n",
      "NORVASC\n",
      " away from children. Store \n",
      "NORVASC\n",
      " Tablets at room temperature\n",
      "(between 59° and 86°F). Keep \n",
      "NORVASC\n",
      " out of the light. Do not store in the bathroom.\n",
      "Keep \n",
      "NORVASC\n",
      " in a dry place.\n",
      "General advice about NORVASC\n",
      "the best treatment for you.\n",
      "are breast-feeding. NORVASC passes into your milk.\n",
      "Take \n",
      "NORVASC\n",
      " once a day, with or without food.\n",
      "It may be easier to take your dose if you do it at the same time every day, such as\n",
      "with breakfast or dinner, or at bedtime. Do not take more than one dose of\n",
      "NORVASC\n",
      " at a time.\n",
      "If you miss a dose, take it as soon as you remember. \n",
      "Do not take \n",
      "NORVASC\n",
      " if it\n",
      "has been more than 12 hours since you missed your last dose. Wait and take the\n",
      "next dose at your regular time.\n",
      "Other medicines:\n",
      " You can use nitroglycerin and \n",
      "NORVASC\n",
      " together. If you take\n",
      "nitroglycerin for angina, don't stop taking it while you are taking \n",
      "NORVASC.\n",
      "While you are taking \n",
      "NORVASC\n",
      ", \n",
      "do not stop taking your other prescription\n",
      "medicines, including any other blood pressure medicines, without talking to your\n",
      "doctor.\n",
      "If you took too much \n",
      "NORVASC\n",
      ", call your doctor or Poison Control Center, or go\n",
      "to the nearest hospital emergency room right away.\n",
      "Do not\n",
      " start any new prescription or non-prescription medicines or supplements,\n",
      "unless you check with your doctor first.\n",
      "swelling of your legs or ankles\n",
      "tiredness, extreme sleepiness\n",
      "stomach pain, nausea\n",
      "dizziness\n",
      "flushing (hot or warm feeling in your face)\n",
      "arrhythmia (irregular heartbeat)\n",
      "heart palpitations (very fast heartbeat)\n",
      "muscle rigidity, tremor and/or abnormal muscle movement\n",
      "------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "test_set_df = testset.to_pandas()\n",
    "\n",
    "for index, row in enumerate(test_set_df.head(3).iterrows()):\n",
    "    print(f\"Question {index + 1}: {row[1]['question']}\")\n",
    "    print(f\"Reference answer: {row[1]['reference_answer']}\")\n",
    "    print(\"Reference context:\")\n",
    "    print(row[1]['reference_context'])\n",
    "    print(\"------------------------------\", end=\"\\n\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "testset.save(\"test-set.jsonl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn(question, history=None):\n",
    "    return chain.invoke({\"question\": question})\n",
    "   "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c049195ebf38433894d4b3892d823fd7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/10 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "82548bccd913468d978689a8099730a9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/10 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"c6042a00-6efb-41ec-b2bc-4ba1555ba1b0\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"c6042a00-6efb-41ec-b2bc-4ba1555ba1b0\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"c6042a00-6efb-41ec-b2bc-4ba1555ba1b0\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        70.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=70.0 class=\" progress-green \">70.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        33.33%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=33.33333333333333 class=\" progress-orange \">33.33%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        50.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=50.0 class=\" progress-orange \">50.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">70%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on improving the performance on complex questions by enhancing the Generator component. Additionally, ensure equal attention is given to all topics in the knowledge base to balance the overall performance of the RAG system.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"cd4d25c5-8ce8-4659-96a6-aa80984ba0e4\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1441\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1443\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1450\",\"attributes\":{\"factors\":[\"Amlodipine Side Effects\",\"Malaria Prophylaxis\",\"Metoprolol Pharmacokinetics\",\"Pharmaceutical Ingredients\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1451\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1452\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1448\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1470\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1438\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1439\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1440\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"qqqqqqqqUEAAAAAAAABZQAAAAAAAAFlAAAAAAAAASUA=\"},\"shape\":[4],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Amlodipine Side Effects\",\"Malaria Prophylaxis\",\"Metoprolol Pharmacokinetics\",\"Pharmaceutical Ingredients\"]],[\"colors\",[\"#fdbe6e\",\"#006837\",\"#006837\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1471\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1472\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1467\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1468\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1469\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1479\",\"attributes\":{\"data_source\":{\"id\":\"p1438\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1480\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1481\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1476\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1477\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1478\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1489\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1483\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1484\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1485\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1490\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1491\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1486\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1487\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1488\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1449\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1463\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1458\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1459\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1460\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1461\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1453\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1454\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1455\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1456\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1457\",\"attributes\":{\"axis\":{\"id\":\"p1453\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1462\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1458\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1482\",\"attributes\":{\"location\":70.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1492\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1493\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1489\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"cd4d25c5-8ce8-4659-96a6-aa80984ba0e4\",\"roots\":{\"p1441\":\"c296b741-8008-4bb4-8763-cea1ccbea632\"},\"root_ids\":[\"p1441\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"c296b741-8008-4bb4-8763-cea1ccbea632\" data-root-id=\"p1441\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"7949a191-3357-4b24-8b04-061d301649b2\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1372\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1302\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1251\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1260\",\"attributes\":{\"start\":8.888234281539917,\"end\":24.644878578186034}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1261\",\"attributes\":{\"start\":-11.353830933570862,\"end\":-0.5755528211593628}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1262\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1263\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1258\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1291\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1248\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1249\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1250\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"80peQXU/YUF6K1pBgz9hQZyPeUGgAXtBnzJnQQjPbkGjc3ZBvqyAQXjOfUHJO3VBdb55QXh5fUHiG3lBjBh3QcI/fUG2IoRBsemCQULNfUHMYYJBcQJ6Qej9fkGRGoVB9riCQY9LgEENvnlBKbhXQTLdXUEA2mVBxKljQQJwW0H/S1lBS2ZjQXJiXEEkzmdBqYlhQRmoVkHYBlVBXZpYQSBOYkHe9F1B6g1cQT7cYUH6GlpBXV5hQYqIXEGWYVNBeAJcQYE8XUHhAFJBesZUQdzcTkHX71BBnvFeQXvfZ0EZamVByO1rQfDEakGNrG5BZSdtQQg9jUHpdYlBko6NQe9AkUG7WY9B0YuOQdPDkUEXWIpBxPOKQSxmjEELWpBB7UKNQf92jkG7iJNB1HuTQU9Sl0F2P5VBWkuLQcn+j0F/9pFBw3SOQVSaiUFs6IpBgS2HQZ8UiUGzLItBsIqLQfwHg0H+84JBquyFQSruhEFXloJBzIuGQdVyiEHx5IZBR++EQWQdgUEbq4RB96B5QXDcc0Eprn9B0+2BQaZwe0HvTH1Boel4QbXUhEHSlolBIoqBQfF9fEFN03tBLhF+QWJRQkHjHEFB2cdBQRWVPEEJUUNBF3lAQSpiR0GSl0VB4Rw/QcFaRkGRQklBMjw7QQviRkHlOUtBOtOBQZgvhEG7YIFB8p5LQckXU0GPe3lBv9luQbI5cEFC6HJB2xhwQUgSa0GPzWtBMR5xQUBwF0GXGRdB8dkVQVHlHEGbCBtBLdgmQQu1JUFHkh5BehUgQYRvHkH4yyJB4S8XQVphJEHI+idBSeErQR9JLUEH5SNB2X4lQbBVIkEbqytBXzclQfP3HEELJxZBNTowQbC7ekHgl3VB\"},\"shape\":[165],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[165],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Others\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Metformin Hydrochloride\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Metoprolol Pharmacokinetics\",\"Others\",\"Others\",\"Others\",\"Pharmaceutical Ingredients\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Albuterol Inhalation Solution\",\"Albuterol Inhalation Solution\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Malaria Prophylaxis\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\"]],[\"id\",[0,1,2,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167]],[\"content\",[\"12 HOUR NASAL DECONGESTANT- pseudoephedrine hydrochloride tablet, film\\\\ncoated \\\\n \\\\nCARDINAL HEALTH\\\\n----------\\\\nPseudoephedrine hydrochloride\\\\nDrug Facts\\\\nActive ingredient (in each tablet)\\\\nPseudoephedrine HCl, USP 120 mg\\\\nPurpose\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves nasal congestion due to the common cold, hay fever or other\\\\nupper respiratory allergies\\\\ntemporarily relieves sinus congestion and pressure\\\\nWarnings\\\\nDo not use\\\\n if you are now taking a prescription monoamine oxidase inhibitor (MAOI)...\",\"Directions\\\\nadults and children 12 years\\\\nand over\\\\ntake 1 tablet every 12\\\\nhours\\\\ndo not take more than 2\\\\ntablets in 24 hours\\\\nchildren under 12 years\\\\ndo not use this product in\\\\nchildren under 12 years of\\\\nage\\\\nOther information\\\\nstore at 59\\\\u00b0 to 77\\\\u00b0 F in a dry place. Protect from light\\\\nTAMPER EVIDENT: DO NOT USE IF BLISTER UNITS ARE TORN, BROKEN OR\\\\nSHOW ANY SIGNS OF TAMPERING.\\\\nInactive ingredients\\\\ncastor oil, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline\\\\ncellulose, titani...\",\"COMPARE TO\\\\nSUDAFED\\\\n SINUS\\\\nCONGESTION 12 HOUR**\\\\nactive ingredient\\\\n100% Money Back Guarantee\\\\n\\\\u00ae\",\"12 HOUR NASAL DECONGESTANT  \\\\npseudoephedrine hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:70000-0656\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPSEUDOEPHEDRINE HYDROCHLORIDE\\\\n (UNII: 6V9V2RYJ8N)\\\\n(PSEUDOEPHEDRINE - UNII:7CUC9DDI9F)\\\\nPSEUDOEPHEDRINE\\\\nHYDROCHLORIDE\\\\n120 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCASTOR OIL\\\\n (UNII: D5340Y2I9G)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU...\",\"CARDINAL HEALTH\\\\nRegistrant - \\\\nOhm Laboratories Inc. (184769029)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nOhm Laboratories Inc.\\\\n051565745\\\\nmanufacture(70000-0656)\\\\n \\\\nRevised: 5/2024\",\"ADVIL- ibuprofen tablet, coated \\\\n \\\\nHaleon US Holdings LLC\\\\n----------\\\\nDrug Facts\\\\nActive Ingredient\\\\nAdvil Tablets (in each tablet)\\\\nIbuprofen 200 mg (NSAID)*\\\\n*nonsteroidal anti-inflammatory drug\\\\nAdvil Caplets (in each caplet)\\\\nIbuprofen 200 mg (NSAID)*\\\\n*nonsteroidal anti-inflammatory drug\\\\nAdvil Gel Caplets (in each gel caplet)\\\\nIbuprofen 200 mg (NSAID)*\\\\n*nonsteroidal anti-inflammatory drug\\\\nPurpose\\\\nPain reliever/Fever reducer\\\\nUses\\\\ntemporarily relieves minor aches and pains due to:\\\\nheadache\\\\ntoothache\\\\nb...\",\"asthma (wheezing)\\\\nshock\\\\nskin reddening\\\\nrash\\\\nblisters\\\\nIf an allergic reaction occurs, stop use and seek medical help right away.\\\\nStomach bleeding warning:\\\\nThis product contains an NSAID, which may cause severe stomach bleeding. The chance\\\\nis higher if you\\\\nare age 60 or older\\\\nhave had stomach ulcers or bleeding problems\\\\ntake a blood thinning (anticoagulant) or steroid drug\\\\ntake other drugs containing prescription or non-prescription NSAIDs [aspirin,\\\\nibuprofen, naproxen, or others]\\\\nhave 3 or more a...\",\"vomit blood\\\\nhave bloody or black stools\\\\nhave stomach pain that does not get better\\\\nyou have symptoms of heart problems or stroke:\\\\nchest pain\\\\ntrouble breathing\\\\nweakness in one part or side of body\\\\nslurred speech\\\\nleg swelling\\\\npain gets worse or lasts more than 10 days\\\\nfever gets worse or lasts more than 3 days\\\\nredness or swelling is present in the painful area\\\\nany new symptoms appear\\\\nIf pregnant or breast-feeding,\\\\nask a health professional before use. It is especially important not to use ibuprofe...\",\"if pain or fever does not respond to 1 gel caplet, 2 gel caplets may be used\\\\ndo not exceed 6 gel caplets in 24 hours, unless directed by a doctor\\\\nchildren under 12 years: ask a doctor\\\\nOther information\\\\nread all warnings and directions before use. Keep carton.\\\\nstore at 20-25\\\\u00b0C (68-77\\\\u00b0F)\\\\navoid excessive heat above 40\\\\u00b0C (104\\\\u00b0F)\\\\nInactive ingredients\\\\nAdvil Tablets\\\\nacetylated monoglycerides, colloidal silicon dioxide, corn starch, croscarmellose sodium,\\\\nmethylparaben, microcrystalline cellulose, pharm...\",\"PRINCIPAL DISPLAY PANEL - 300 Tablet Bottle Label\\\\nAdvil \\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n300 Coated Tablets\\\\nTablets\\\\nPRINCIPAL DISPLAY PANEL - 115 Tablet Bottle Carton\\\\n15 \\\\nFREE \\\\n\\\\u00ae\",\"TABLETS\\\\nAdvil \\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n115 \\\\nCoated Tablets\\\\nTablets\\\\nPRINCIPAL DISPLAY PANEL - 225 Caplet Bottle Carton\\\\n25 \\\\nFREE \\\\nCAPLETS\\\\nAdvil \\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n225 \\\\nCoated Caplets* \\\\n*Capsule-Shaped Tablets\\\\nCaplets\\\\n\\\\u00ae\\\\n\\\\u00ae\",\"PRINCIPAL DISPLAY PANEL - 24 Tablet Bottle Carton\\\\nNDC 0573-0150-20\\\\nAdvil \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n24 Coated Tablets\\\\nTablets\\\\n000067199 Front Carton\",\"PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label\\\\nAdvil \\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n100 Tablets\\\\nTablets\\\\nREAD AND KEEP CARTON FOR COMPLETE \\\\nWARNINGS AND INFORMATION\\\\nDo Not Use if seal under bottle cap imprinted with \\\\n\\\\\"SEALED for YOUR PROTECTION\\\\\" is broken or missing.\\\\nPRINCIPAL DISPLAY PANEL - 24 Caplet Bottle Carton\\\\nNDC 0573-0160-20\\\\nAdvil\\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n24 Coated Caplets*\\\\n \\\\n*Capsule-Shaped Tablets\\\\nCaplets\\\\n0000...\",\"Principal Display Panel - 225 Caplet Bottle Label\\\\nNDC 0573-1711-14\\\\nAdvil\\\\u00ae\\\\n \\\\nIbuprofen Tablets, 200 mg \\\\nPain Reliever/Fever Reducer (NSAID)\\\\n225 Caplets\\\\nCaplets\\\\nREAD AND KEEP CARTON FOR COMPLETE\\\\n \\\\nWARNINGS AND INFORMATION\\\\nPAA085439 Bottle Label\",\"ADVIL  \\\\nibuprofen tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:0573-0165\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI10QM) \\\\n(IBUPROFEN - UNII:WK2XYI10QM)\\\\nIBUPROFEN\\\\n200 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nFD&amp;C YELLOW NO. 6\\\\n (UNII: H77VEI93A8)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)...\",\"TITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nTRIACETIN\\\\n (UNII: XHX3C3X673)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nbrown (one side is brown while the other side is yellow)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\nAdvil\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0573-0165-\\\\n20\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n1\\\\n24 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n2\\\\nNDC:0573-0165-\\\\n30\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n2\\\\n50 \\\\nin 1 ...\",\"Product Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:0573-0154\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI10QM) \\\\n(IBUPROFEN - UNII:WK2XYI10QM)\\\\nIBUPROFEN\\\\n200 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nMETHYLPARABEN\\\\n (UNII: A2I8C7HI9T)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n ...\",\"3\\\\nNDC:0573-0154-\\\\n17\\\\n3000 \\\\nin 1 CASE\\\\n05/18/1984\\\\n3\\\\n2 \\\\nin 1 POUCH; Type 0: Not a Combination\\\\nProduct\\\\n4\\\\nNDC:0573-0154-\\\\n89\\\\n50 \\\\nin 1 CASE\\\\n05/18/1984\\\\n4\\\\n2 \\\\nin 1 POUCH; Type 0: Not a Combination\\\\nProduct\\\\n5\\\\nNDC:0573-0154-\\\\n84\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n5\\\\n225 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n6\\\\nNDC:0573-0154-\\\\n98\\\\n300 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n05/18/1984\\\\n7\\\\nNDC:0573-0154-\\\\n16\\\\n3 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n7\\\\n2 \\\\nin 1 POUCH; Type 0: Not a Combination\\\\nProduct\\\\n8\\\\nNDC:0573-0154-\\\\n60\\\\n360 \\\\ni...\",\"METHYLPARABEN\\\\n (UNII: A2I8C7HI9T)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nPROPYLPARABEN\\\\n (UNII: Z8IX2SC1OH)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nSODIUM BENZOATE\\\\n (UNII: OJ245FE5EU)\\\\n \\\\nSODIUM LAURYL SULFATE\\\\n (UNII: 368GB5141J)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: 4ELV7Z65AP)\\\\n \\\\nSUCROSE\\\\n (UNII: C151H8M554)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nWHITE WAX\\\\n (UNII: 7G1J5DA97F)\\\\n \\\\nDIACETYLATED MONOGLYCERIDES\\\\n (UNII: 5Z17386USF)\\\\n \\\\nProduct Chara...\",\"8\\\\n115 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA018989\\\\n05/18/1984\\\\nADVIL  \\\\nibuprofen tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:0573-0161\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI10QM) \\\\n(IBUPROFEN - UNII:WK2XYI10QM)\\\\nIBUPROFEN\\\\n200 mg\\\\nIna...\",\"Contains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0573-0161-\\\\n35\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n1\\\\n150 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n2\\\\nNDC:0573-0161-\\\\n51\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n2\\\\n200 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n3\\\\nNDC:0573-0161-\\\\n85\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n3\\\\n225 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n4\\\\nNDC:0573-0161-\\\\n65\\\\n65 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n05/01/2017\\\\nMarketing Information\\\\n...\",\"HYPROMELLOSE, UNSPECIFIED\\\\n (UNII: 3NXW29V3WO)\\\\n \\\\nMEDIUM-CHAIN TRIGLYCERIDES\\\\n (UNII: C9H2L21V7U)\\\\n \\\\nPROPYL GALLATE\\\\n (UNII: 8D4SNN7V92)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nSODIUM LAURYL SULFATE\\\\n (UNII: 368GB5141J)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: 4ELV7Z65AP)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nTRIACETIN\\\\n (UNII: XHX3C3X673)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nbrown (one side is brown while the other side is yellow)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL\\\\nSi...\",\"Inactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nMETHYLPARABEN\\\\n (UNII: A2I8C7HI9T)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nPROPYLPARABEN\\\\n (UNII: Z8IX2SC1OH)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nSODIUM BENZOATE\\\\n (UNII: OJ245FE5EU)\\\\n \\\\nSODIUM LAURYL SULFATE\\\\n (UNII: 368GB5141J)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: ...\",\"6\\\\nProduct\\\\n7\\\\nNDC:0573-0150-\\\\n42\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n7\\\\n150 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA018989\\\\n05/18/1984\\\\nADVIL  \\\\nibuprofen tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:0573-0160\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI1...\",\"Shape\\\\nOVAL\\\\nSize\\\\n15mm\\\\nFlavor\\\\nImprint Code\\\\nAdvil\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0573-0160-\\\\n20\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n1\\\\n24 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n2\\\\nNDC:0573-0160-\\\\n30\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n2\\\\n50 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n3\\\\nNDC:0573-0160-\\\\n40\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n3\\\\n100 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n4\\\\nNDC:0573-0160-\\\\n25\\\\n1 \\\\nin 1 CARTON\\\\n05/18/1984\\\\n4\\\\n36 \\\\nin 1 BO...\",\"Route of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI10QM) \\\\n(IBUPROFEN - UNII:WK2XYI10QM)\\\\nIBUPROFEN\\\\n200 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nMETHYLPARABEN\\\\n (UNII: A2I8C7HI9T)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nPROPYLPARABEN\\\\n (UNII: Z8IX2SC1OH)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B7...\",\"Haleon US Holdings LLC\\\\nLabeler - \\\\nHaleon US Holdings LLC \\\\n(079944263)\\\\n \\\\nRevised: 4/2024\",\"CONEX PEDIATRIC- dexbrompheniramine maleate, pseudoephedrine hcl liquid \\\\nLlorens Pharmaceutical International Division\\\\n----------\\\\nLlorens-ConexPed 803\\\\nActive Ingredients (in each 5 mL tsp.)\\\\nDexbrompheniramine Maleate, USP .......... 1 mg .................... Antihistamine\\\\nPseudoephedrine HCL, USP ............ 30 mg ...................... Nasal Decongestant\\\\nAntihistamine\\\\nNasal Decongestant\\\\nUses\\\\nTemporarily relieves nasal congestion due to the common cold, hay fever or other\\\\nupper repiratory aller...\",\"Stop use and ask a doctor if\\\\nnervousness, dizziness or sleeplessness occur\\\\nsymptoms do not improve within 7 days or occur with a fever.\\\\nKeep out of the reach of children.\\\\nIn case of overdose, get medical help or contact\\\\na Poison Control Center right away.\\\\nIf pregnant or breast-feeding,\\\\nask a Health Professional before use.\\\\nDirections:\\\\nDo not exceed more than 4 doses in any 24-hour period or as directed by a\\\\ndoctor.\\\\nAge\\\\nDose\\\\nAdults and children 12 years of age and\\\\nover\\\\ntake two teaspoonfuls (10 m...\",\"Llorens Pharmaceutical International Division\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nDEXBROMPHENIRAMINE MALEATE\\\\n (UNII: BPA9UT29BS)\\\\n(DEXBROMPHENIRAMINE - UNII:75T64B71RP)\\\\nDEXBROMPHENIRAMINE\\\\nMALEATE\\\\n1 mg\\\\n in 5 mL\\\\nPSEUDOEPHEDRINE HYDROCHLORIDE\\\\n (UNII: 6V9V2RYJ8N)\\\\n(PSEUDOEPHEDRINE - UNII:7CUC9DDI9F)\\\\nPSEUDOEPHEDRINE\\\\nHYDROCHLORIDE\\\\n30 mg\\\\n in 5 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\n...\",\"METFORMIN HYDROCHLORIDE- metformin hydrochloride tablet \\\\n \\\\nAmneal Pharmaceuticals LLC\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use \\\\nMETFORMIN\\\\nHYDROCHLORIDE TABLETS\\\\n safely and effectively. See full prescribing information for\\\\nMETFORMIN HYDROCHLORIDE TABLETS\\\\n. \\\\n \\\\nMETFORMIN HYDROCHLORIDE\\\\n tablets, for oral use \\\\nInitial U.S. Approval: 1995\\\\nWARNING: LACTIC ACIDOSIS\\\\nSee full prescribing information for complete boxed warning.\\\\nPostm...\",\"CONTRAINDICATIONS\\\\nSevere renal impairment (eGFR below 30 mL/min/1.73 m\\\\n). (\\\\n4\\\\n, \\\\n5.1\\\\n)\\\\nHypersensitivity to metformin. (\\\\n4\\\\n)\\\\nAcute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. (\\\\n4\\\\n)\\\\nWARNINGS AND PRECAUTIONS\\\\nLactic Acidosis:\\\\n See boxed warning. (\\\\n5.1\\\\n)\\\\nVitamin B\\\\n Deficiency:\\\\n Metformin may lower vitamin B\\\\n levels. Measure hematological parameters\\\\nannually and vitamin B\\\\n at 2 to 3 year intervals and manage any abnormalities. (\\\\n5.2\\\\n)\\\\nHypoglycemia with Concomi...\",\"6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\n8.2 Lactation\\\\n8.3 Females and Males of Reproductive Potential\\\\n8.4 Pediatric Use\\\\n8.5 Geriatric Use\\\\n8.6 Renal Impairment\\\\n8.7 Hepatic Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 Metformin Hydrochloride Tablets\\\\n16    HOW SUPPLIED/STOR...\",\"WARNING: LACTIC ACIDOSIS\\\\nPostmarketing cases of metformin-associated lactic acidosis have\\\\nresulted in death, hypothermia, hypotension, and resistant\\\\nbradyarrhythmias. The onset of metformin-associated lactic acidosis is\\\\noften subtle, accompanied only by nonspecific symptoms such as\\\\nmalaise, myalgias, respiratory distress, somnolence, and abdominal pain.\\\\nMetformin-associated lactic acidosis was characterized by elevated\\\\nblood lactate levels (&gt; 5 mmol/Liter), anion gap acidosis (without\\\\nevidence o...\",\"Increase dosage in increments of 500 mg weekly on the basis of glycemic control\\\\nand tolerability, up to a maximum of 2,000 mg per day, given in divided doses twice\\\\ndaily.\\\\n2.3 Recommendations for Use in Renal Impairment\\\\nAssess renal function prior to initiation of metformin hydrochloride tablets and\\\\nperiodically thereafter.\\\\nMetformin hydrochloride tablets are contraindicated in patients with an estimated\\\\nglomerular filtration rate (eGFR) below 30 mL/minute/1.73 m\\\\n.\\\\nInitiation of metformin hydroch...\",\"5.1 Lactic Acidosis\\\\nThere have been postmarketing cases of metformin-associated lactic acidosis, including\\\\nfatal cases. These cases had a subtle onset and were accompanied by nonspecific\\\\nsymptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased\\\\nsomnolence; however, hypotension and resistant bradyarrhythmias have occurred with\\\\nsevere acidosis. Metformin-associated lactic acidosis was characterized by elevated\\\\nblood lactate concentrations (&gt; 5 mmol/L), anion gap acidos...\",\"the patient\\\\u2019s age because elderly patients have a greater likelihood of having hepatic,\\\\nrenal, or cardiac impairment than younger patients. Assess renal function more\\\\nfrequently in elderly patients.\\\\nRadiologic studies with contrast \\\\n\\\\u2014 Administration of intravascular iodinated contrast\\\\nagents in metformin-treated patients has led to an acute decrease in renal function\\\\nand the occurrence of lactic acidosis. Stop metformin hydrochloride at the time of, or\\\\nprior to, an iodinated contrast imaging pro...\",\"5.4 Macrovascular Outcomes\\\\nThere have been no clinical studies establishing conclusive evidence of macrovascular\\\\nrisk reduction with metformin hydrochloride.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are also discussed elsewhere in the labeling:\\\\nLactic Acidosis \\\\n[see \\\\nBoxed Warning\\\\n and\\\\n Warnings and Precautions (5.1)\\\\n]\\\\nVitamin B\\\\n Deficiency \\\\n[see \\\\nWarnings and Precautions (5.2)\\\\n]\\\\nHypoglycemia \\\\n[see \\\\nWarnings and Precautions (5.3)\\\\n]\\\\n6.1 Clinical Studies Experience\\\\nBecause clinical tria...\",\"In clinical trials with metformin hydrochloride in pediatric patients with type 2 diabetes\\\\nmellitus, the profile of adverse reactions was similar to that observed in adults.\\\\n6.2 Postmarketing Experience\\\\nThe following adverse reactions have been identified during post approval use of\\\\nmetformin. Because these reactions are reported voluntarily from a population of\\\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\\\ncausal relationship to drug exposure.\\\\nCho...\",\"Intervention:\\\\nWhen such drugs are withdrawn from a patient receiving metformin\\\\nhydrochloride, observe the patient closely for hypoglycemia.\\\\nExamples:\\\\nThiazides and other diuretics, corticosteroids, phenothiazines, thyroid\\\\nproducts, estrogens, oral contraceptives, phenytoin, nicotinic acid,\\\\nsympathomimetics, calcium channel blockers, and isoniazid.\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nRisk Summary\\\\nLimited data with metformin hydrochloride in pregnant women are not sufficient to\\\\ndetermine a...\",\"surface area comparisons for rats and rabbits, respectively. Determination of fetal\\\\nconcentrations demonstrated a partial placental barrier to metformin.\\\\n8.2 Lactation\\\\nRisk Summary\\\\nLimited published studies report that metformin is present in human milk \\\\n[see Data].\\\\nHowever, there is insufficient information to determine the effects of metformin on the\\\\nbreastfed infant and no available information on the effects of metformin on milk\\\\nproduction. Therefore, the developmental and health benefits of...\",\"8.6 Renal Impairment\\\\nMetformin is substantially excreted by the kidney, and the risk of metformin\\\\naccumulation and lactic acidosis increases with the degree of renal impairment.\\\\nMetformin hydrochloride is contraindicated in severe renal impairment, patients with an\\\\nestimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m\\\\n[see \\\\nDosage and\\\\nAdministration (2.3)\\\\n, \\\\nContraindications (4)\\\\n, \\\\nWarnings and Precautions (5.1)\\\\n, \\\\nand \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\n8.7 Hepatic Impairment\\\\nUse of...\",\"natural flavors.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nMetformin is an antihyperglycemic agent which improves glucose tolerance in patients\\\\nwith type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.\\\\nMetformin decreases hepatic glucose production, decreases intestinal absorption of\\\\nglucose, and improves insulin sensitivity by increasing peripheral glucose uptake and\\\\nutilization. With metformin therapy, insulin secretion remains unchanged while fasting\\\\ninsulin ...\",\"extended-release tablets.\\\\nDistribution\\\\nThe apparent volume of distribution (V/F) of metformin following single oral doses of\\\\nmetformin hydrochloride 850 mg averaged 654 \\\\u00b1 358 L. Metformin is negligibly bound\\\\nto plasma proteins. Metformin partitions into erythrocytes, most likely as a function of\\\\ntime.\\\\nMetabolism\\\\nIntravenous single-dose studies in normal subjects demonstrate that metformin is\\\\nexcreted unchanged in the urine and does not undergo hepatic metabolism (no\\\\nmetabolites have been identif...\",\"Healthy,\\\\nnondiabetic adults:\\\\n500 mg single-dose\\\\n(24)\\\\n850 mg single-dose\\\\n(74)\\\\n850 mg three times\\\\ndaily for 19 doses\\\\n (9)\\\\n1.03 (\\\\u00b10.33)\\\\n1.60 (\\\\u00b10.38)\\\\n2.01 (\\\\u00b10.42)\\\\n2.75 (\\\\u00b10.81)\\\\n2.64 (\\\\u00b10.82)\\\\n1.79 (\\\\u00b10.94)\\\\n600 (\\\\u00b1132)\\\\n552 (\\\\u00b1139)\\\\n642 (\\\\u00b1173)\\\\nAdults with type 2\\\\ndiabetes mellitus:\\\\n850 mg single-dose\\\\n(23)\\\\n850 mg three times\\\\ndaily for 19 doses\\\\n (9)\\\\n1.48 (\\\\u00b10.5)\\\\n1.90 (\\\\u00b10.62)\\\\n3.32 (\\\\u00b11.08)\\\\n2.01 (\\\\u00b11.22)\\\\n491 (\\\\u00b1138)\\\\n550 (\\\\u00b1160)\\\\nElderly\\\\n, healthy\\\\nnondiabetic adults:\\\\n850 mg single-dose\\\\n(12)\\\\n2.45 (\\\\u00b10.70)\\\\n2.71 (\\\\u00b11.05)\\\\n412...\",\"Race\\\\nNo studies of metformin pharmacokinetic parameters according to race have been\\\\nperformed.\\\\nDrug Interactions \\\\nIn Vivo\\\\n Assessment of Drug Interactions\\\\nTable 5: Effect of Co-administered Drug on Plasma Metformin Systemic\\\\nExposure\\\\nCo-\\\\nadministered\\\\nDrug\\\\nDose of Co-\\\\nadministered\\\\nDrug\\\\n*\\\\nDose of\\\\nMetformin\\\\n*\\\\nGeometric Mean Ratio (ratio\\\\nwith/without co-administered drug) No\\\\nEffect = 1.00\\\\nAUC\\\\nC\\\\nNo dosing adjustments required for the following:\\\\nGlyburide\\\\n5 mg\\\\n850 mg\\\\nmetformin\\\\n0.91\\\\n0.93\\\\nFurosemide\\\\n40 m...\",\"Ratio of arithmetic means\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nLong-term carcinogenicity studies have been performed in rats (dosing duration of 104\\\\nweeks) and mice (dosing duration of 91 weeks) at doses up to and including 900\\\\nmg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately 3\\\\ntimes the maximum recommended human daily dose of 2,550 mg based on body\\\\nsurface area comparisons. No evidence of carcinogenicity with metformi...\",\"Mean baseline body weight was 201 lbs and 206 lbs in the metformin hydrochloride and\\\\nplacebo arms, respectively. Mean change in body weight from baseline to week 29 was -\\\\n1.4 lbs and -2.4 lbs in the metformin hydrochloride and placebo arms, respectively. A\\\\n29-week, double-blind, placebo-controlled study of metformin hydrochloride and\\\\nglyburide, alone and in combination, was conducted in obese patients with type 2\\\\ndiabetes mellitus who had failed to achieve adequate glycemic control while on maxi...\",\"Pediatric Clinical Studies\\\\nA double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with\\\\ntype 2 diabetes mellitus (mean FPG 182.2 mg/dL), treatment with metformin\\\\nhydrochloride (up to 2,000 mg/day) for up to 16 weeks (mean duration of treatment 11\\\\nweeks) was conducted. The results are displayed in Table 9.\\\\nTable 9: Mean Change in Fasting Plasma Glucose at Week 16 Comparing\\\\nMetformin Hydrochloride\\\\n vs Placebo in Pediatric Patients\\\\nwith Type 2\\\\nDiabetes Mellitus\\\\nMetformin ...\",\"Metformin Hydrochloride Tablets USP, \\\\n1,000 mg\\\\n are blackberry flavored, white to off-\\\\nwhite, oval, biconvex, bisected, film-coated tablets debossed \\\\u201cIP 220\\\\u201d on obverse and\\\\n\\\\u201c1000\\\\u201d on the reverse.\\\\nThey are available as follows:\\\\nBottles of 30:              NDC 65162-220-03\\\\nBottles of 100:            NDC 65162-220-10\\\\nBottles of 500:            NDC 65162-220-50\\\\nBottles of 1,000:         NDC 65162-220-11\\\\n16.2 Storage\\\\nStore at 20\\\\u00b0 to 25\\\\u00b0C (68\\\\u00b0 to 77\\\\u00b0F); excursions permitted between 15\\\\u00b0 to 30\\\\u00b0C (59\\\\u00b0 to...\",\"Bridgewater, NJ 08807\\\\nRev. 08-2023-04\\\\nPATIENT INFORMATION\\\\nMetformin hydrochloride \\\\n(met for\\\\u2019 min hye\\\\u201ddroe klor\\\\u2019 ide)\\\\n Tablets, USP\\\\nRead the Patient Information that comes with metformin hydrochloride tablets before\\\\nyou start taking it and each time you get a refill. There may be new information. This\\\\nleaflet does not take the place of talking with your healthcare provider about your\\\\nmedical condition or treatment.\\\\nWhat is the most important information I should know about \\\\nmetformin\\\\nhydrochlorid...\",\"hydrochloride. Metformin hydrochloride tablets are used with diet and exercise to\\\\nhelp control high blood sugar (hyperglycemia) in adults with type 2 diabetes.\\\\nMetformin hydrochloride tablets are not for people with type 1 diabetes.\\\\nMetformin hydrochloride tablets are not for people with diabetic ketoacidosis\\\\n(increased ketones in your blood or urine).\\\\nMetformin hydrochloride tablets help control your blood sugar in a number of ways.\\\\nThese include helping your body respond better to the insulin ...\",\"to feed your baby while you take metformin hydrochloride tablets.\\\\nTell your healthcare provider about all the medicines you take, \\\\nincluding\\\\nprescription and nonprescription medicines, vitamins, and herbal supplements. Know\\\\nthe medicines you take. Keep a list of them to show your healthcare provider and\\\\npharmacist when you get a new medicine.\\\\nMetformin hydrochloride tablets may affect the way other medicines work, and other\\\\nmedicines may affect how metformin hydrochloride tablet works.\\\\nCan \\\\nmetf...\",\"Lactic acidosis. Metformin, the active ingredient in \\\\nmetformin\\\\nhydrochloride tablets\\\\n, can cause a rare but serious condition called lactic\\\\nacidosis (a buildup of an acid in the blood) that can cause death. Lactic\\\\nacidosis is a medical emergency and must be treated in the hospital.\\\\nCall your doctor right away if you have any of the following symptoms, which could be\\\\nsigns of lactic acidosis:\\\\nyou feel cold in your hands or feet\\\\nyou feel dizzy or lightheaded\\\\nyou have a slow or irregular heartbeat...\",\"prescribed. Do not share your medicine with other people.\\\\nWhat are the ingredients of \\\\nmetformin hydrochloride tablets\\\\n?\\\\nActive ingredients of metformin hydrochloride tablets: metformin hydrochloride, USP.\\\\nInactive ingredients in each tablet of metformin hydrochloride tablets: povidone,\\\\nmicrocrystalline cellulose, croscarmellose sodium and magnesium stearate. In addition,\\\\nthe coating for the 500 mg, 850 mg, and 1000 mg tablets contain polyethylene glycol,\\\\npolyvinyl alcohol, titanium dioxide, tal...\",\"NDC 65162-218-10\\\\nMetformin Hydrochloride Tablets USP, 500 mg\\\\n100 Tablets\\\\nRx only\\\\nAmneal Pharmaceutical LLC\\\\nNDC 65162-219-03\\\\nMetformin Hydrochloride Tablets USP, 850 mg\\\\n30 Tablets\\\\nRx only\\\\nAmneal Pharmaceutical LLC\",\"NDC 65162-219-10\\\\nMetformin Hydrochloride Tablets USP, 850 mg\\\\n100 Tablets\\\\nRx only\\\\nAmneal Pharmaceutical LLC\\\\nNDC 65162-220-03\\\\nMetformin Hydrochloride Tablets USP, 1000 mg\\\\n30 Tablets \\\\nRx only\",\"Amneal Pharmaceutical LLC\\\\nNDC 65162-220-10\\\\nMetformin Hydrochloride Tablets USP, 1000 mg\\\\n100 Tablets \\\\nRx only\\\\nAmneal Pharmaceutical LLC\\\\nMETFORMIN HYDROCHLORIDE  \\\\nmetformin hydrochloride tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:65162-218\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nMETFORMIN HYDROCHLORIDE\\\\n (UNII: 786Z46389E) \\\\n(METFORMIN -\\\\nUNII:9100L32L2N)\\\\nMETFORMIN\\\\nHYDROCHLORIDE\\\\n500 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nACACIA\\\\n (UNII: 5C5403N26O)\\\\n \\\\nMALTODEXTRIN\\\\n (UNII: 7CVR7L4A2D)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nwhite (white to off-w...\",\"Product Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:65162-219\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nMETFORMIN HYDROCHLORIDE\\\\n (UNII: 786Z46389E) \\\\n(METFORMIN -\\\\nUNII:9100L32L2N)\\\\nMETFORMIN\\\\nHYDROCHLORIDE\\\\n850 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nACACIA\\\\n (UNII: 5C5403N26O)\\\\n \\\\nMALTODEXTRIN\\\\n (UNII: 7CVR7L4A2D)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nwhite (white to off-white)\\\\nScore\\\\nno score...\",\"Amneal Pharmaceuticals LLC\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nMETFORMIN HYDROCHLORIDE\\\\n (UNII: 786Z46389E) \\\\n(METFORMIN -\\\\nUNII:9100L32L2N)\\\\nMETFORMIN\\\\nHYDROCHLORIDE\\\\n1000 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nACACIA\\\\n (UNII: 5C5403N26O)\\\\n \\\\nMALTODEXTRIN\\\\n (UNII: 7CVR7L4A2D)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nwhite (white to off-white)\\\\nScore\\\\n2 pieces\\\\nShape\\\\nOVAL\\\\nSize\\\\n19mm\\\\nFlavor\\\\nImprint Code\\\\n...\",\"NORVASC- amlodipine besylate tablet \\\\n \\\\nPFIZER LABORATORIES DIV PFIZER INC\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NORVASC safely and\\\\neffectively. See full prescribing information for NORVASC. \\\\n \\\\nNORVASC\\\\n (amlodipine besylate) Tablets for oral administration \\\\nInitial U.S. Approval: 1992\\\\nINDICATIONS AND USAGE\\\\nNORVASC is a calcium channel blocker and may be used alone or in combination with other\\\\nantihypertensive and antiang...\",\"USE IN SPECIFIC POPULATIONS\\\\n\\\\u2022\\\\n\\\\u2022\\\\nSee 17 for FDA-approved patient labeling.\\\\nRevised: 1/2019\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n1.1 Hypertension\\\\n1.2 Coronary Artery Disease (CAD)\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Adults\\\\n2.2 Children\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypotension\\\\n5.2 Increased Angina or Myocardial Infarction\\\\n5.3 Patients with Hepatic Failure\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing E...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\n1.1 Hypertension\\\\nNORVASC\\\\n is indicated for the treatment of hypertension, to lower blood pressure.\\\\nLowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events,\\\\nprimarily strokes and myocardial infarctions. These benefits have been seen in controlled\\\\ntrials of antihypertensive drugs from a wide variety of pharmacologic classes including\\\\nNORVASC.\\\\nControl of high blood pressure shoul...\",\"2 DOSAGE AND ADMINISTRATION\\\\n2.1 Adults\\\\nThe usual initial antihypertensive oral dose of NORVASC is 5 mg once daily, and the\\\\nmaximum dose is 10 mg once daily.\\\\nSmall, fragile, or elderly patients, or patients with hepatic insufficiency may be started on\\\\n2.5 mg once daily and this dose may be used when adding NORVASC to other\\\\nantihypertensive therapy.\\\\nAdjust dosage according to blood pressure goals. In general, wait 7 to 14 days between\\\\ntitration steps. Titrate more rapidly, however, if clinically w...\",\"4 CONTRAINDICATIONS\\\\nNORVASC is contraindicated in patients with known sensitivity to amlodipine.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypotension\\\\nSymptomatic hypotension is possible, particularly in patients with severe aortic stenosis.\\\\nBecause of the gradual onset of action, acute hypotension is unlikely.\\\\n5.2 Increased Angina or Myocardial Infarction\\\\nWorsening angina and acute myocardial infarction can develop after starting or\\\\nincreasing the dose of NORVASC, particularly in patients with severe obst...\",\"Other adverse reactions that were not clearly dose related but were reported with an\\\\nincidence greater than 1.0% in placebo-controlled clinical trials include the following:\\\\nNORVASC (%)\\\\nPlacebo (%)\\\\n(N=1730)\\\\n(N=1250)\\\\nFatigue\\\\n4.5\\\\n2.8\\\\nNausea\\\\n2.9\\\\n1.9\\\\nAbdominal Pain\\\\n1.6\\\\n0.3\\\\nSomnolence\\\\n1.4\\\\n0.6\\\\nFor several adverse experiences that appear to be drug and dose related, there was a\\\\ngreater incidence in women than men associated with amlodipine treatment as shown in\\\\nthe following table:\\\\nNORVASC\\\\nPlacebo\\\\nMale...\",\"Autonomic Nervous System: \\\\ndry mouth, sweating increased.\\\\nMetabolic and Nutritional: \\\\nhyperglycemia, thirst.\\\\nHemopoietic:\\\\n leukopenia, purpura, thrombocytopenia.\\\\nNORVASC therapy has not been associated with clinically significant changes in routine\\\\nlaboratory tests. No clinically relevant changes were noted in serum potassium, serum\\\\nglucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea\\\\nnitrogen, or creatinine.\\\\nIn the CAMELOT and PREVENT studies \\\\n[see \\\\nClinical S...\",\"Monitor for hypotension when sildenafil is co-administered with amlodipine \\\\n[see \\\\nClinical\\\\nPharmacology (12.2)\\\\n]\\\\n.\\\\n7.2 Impact of Amlodipine on Other Drugs\\\\nSimvastatin\\\\nCo-administration of simvastatin with amlodipine increases the systemic exposure of\\\\nsimvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily \\\\n[see\\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\nImmunosuppressants\\\\nAmlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-\\\\nadministered. Frequent...\",\"Animal Data\\\\nNo evidence of teratogenicity or other embryo/fetal toxicity was found when pregnant\\\\nrats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg\\\\namlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface\\\\narea, respectively) during their respective periods of major organogenesis. However for\\\\nrats, litter size was significantly decreased (by about 50%) and the number of\\\\nintrauterine deaths was significantly increased (about 5-fold) in rats rec...\",\"If massive overdose should occur, initiate active cardiac and respiratory monitoring.\\\\nFrequent blood pressure measurements are essential. Should hypotension occur,\\\\nprovide cardiovascular support including elevation of the extremities and the judicious\\\\nadministration of fluids. If hypotension remains unresponsive to these conservative\\\\nmeasures, consider administration of vasopressors (such as phenylephrine) with\\\\nattention to circulating volume and urine output. As NORVASC is highly protein bound,...\",\"can be detected \\\\nin vitro\\\\n but such effects have not been seen in intact animals at\\\\ntherapeutic doses. Serum calcium concentration is not affected by amlodipine. Within\\\\nthe physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic\\\\ninteraction with the calcium channel receptor is characterized by a gradual rate of\\\\nassociation and dissociation with the receptor binding site, resulting in a gradual onset of\\\\neffect.\\\\nAmlodipine is a peripheral arterial vasodilator that acts d...\",\"man, even when co-administered with beta-blockers to man. Similar findings, however,\\\\nhave been observed in normal or well-compensated patients with heart failure with\\\\nagents possessing significant negative inotropic effects.\\\\nElectrophysiologic Effects: NORVASC does not change sinoatrial nodal function or\\\\natrioventricular conduction in intact animals or man. In patients with chronic stable\\\\nangina, intravenous administration of 10 mg did not significantly alter A-H and H-V\\\\nconduction and sinus nod...\",\"(e.g., itraconazole, clarithromycin) may increase the plasma concentrations of\\\\namlodipine to a greater extent \\\\n[see \\\\nDrug Interactions (7.1)\\\\n]\\\\n.\\\\nImpact of amlodipine on other drugs\\\\nAmlodipine is a weak inhibitor of CYP3A and may increase exposure to CYP3A\\\\nsubstrates.\\\\nCo-administered amlodipine does not affect the exposure to atorvastatin, digoxin,\\\\nethanol and the warfarin prothrombin response time.\\\\nSimvastatin\\\\n: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg\\\\nsimvastatin re...\",\"2\\\\n14 CLINICAL STUDIES\\\\n14.1 Effects in Hypertension\\\\nAdult Patients\\\\nThe antihypertensive efficacy of NORVASC has been demonstrated in a total of 15\\\\ndouble-blind, placebo-controlled, randomized studies involving 800 patients on\\\\nNORVASC and 538 on placebo. Once daily administration produced statistically\\\\nsignificant placebo-corrected reductions in supine and standing blood pressures at 24\\\\nhours postdose, averaging about 12/6 mmHg in the standing position and 13/7 mmHg\\\\nin the supine position in patie...\",\"patients discontinued from the study due to lack of clinical improvement.\\\\n14.4 Effects in Documented Coronary Artery Disease\\\\nIn PREVENT, 825 patients with angiographically documented coronary artery disease\\\\nwere randomized to NORVASC (5\\\\u201310 mg once daily) or placebo and followed for 3\\\\nyears. Although the study did not show significance on the primary objective of change\\\\nin coronary luminal diameter as assessed by quantitative coronary angiography, the\\\\ndata suggested a favorable outcome with respe...\",\"Figure 2 \\\\u2013 Effects on Primary Endpoint of NORVASC versus Placebo across\\\\nSub-Groups\",\"Table 1 below summarizes the significant composite endpoint and clinical outcomes from\\\\nthe composites of the primary endpoint. The other components of the primary endpoint\\\\nincluding cardiovascular death, resuscitated cardiac arrest, myocardial infarction,\\\\nhospitalization for heart failure, stroke/TIA, or peripheral vascular disease did not\\\\ndemonstrate a significant difference between NORVASC and placebo.\\\\nTable 1. \\\\nIncidence of Significant Clinical Outcomes for\\\\nCAMELOT\\\\nClinical\\\\nOutcomes\\\\n \\\\nN (%)\\\\nN...\",\"NORVASC has been compared to placebo in four 8\\\\u201312 week studies of patients with\\\\nNYHA Class II/III heart failure, involving a total of 697 patients. In these studies, there\\\\nwas no evidence of worsened heart failure based on measures of exercise tolerance,\\\\nNYHA classification, symptoms, or left ventricular ejection fraction. In a long-term\\\\n(follow-up at least 6 months, mean 13.8 months) placebo-controlled mortality/morbidity\\\\nstudy of NORVASC 5\\\\u201310 mg in 1153 patients with NYHA Classes III (n=931) o...\",\"Store bottles at controlled room temperature, 59\\\\u00b0 to 86\\\\u00b0F (15\\\\u00b0 to 30\\\\u00b0C) and dispense in\\\\ntight, light-resistant containers (USP).\\\\nLAB-0014-19.0\\\\nNORVASC\\\\n \\\\n(amlodipine besylate)\\\\n \\\\n2.5-mg, 5-mg, and 10-mg tablets\\\\nRead this information carefully before you start taking \\\\nNORVASC\\\\n (NORE-vask) and\\\\neach time you refill your prescription. There may be new information. This information\\\\ndoes not replace talking with your doctor. \\\\nIf you have any questions about \\\\nNORVASC\\\\n,\\\\nask your doctor. \\\\nYour doctor will ...\",\"4.\\\\nHow should I take NORVASC?\\\\n1.\\\\n2.\\\\n3.\\\\n4.\\\\n5.\\\\n6.\\\\nWhat should I avoid while taking NORVASC?\\\\n1.\\\\nWhat are the possible side effects of NORVASC?\\\\nNORVASC \\\\nmay cause the following side effects. \\\\nMost side effects are mild or moderate:\\\\n1.\\\\n2.\\\\n3.\\\\n4.\\\\n5.\\\\n6.\\\\n7.\\\\n8.\\\\nIt is rare, but when you first start taking \\\\nNORVASC\\\\n or increase your dose, you may\\\\nhave a heart attack or your angina may get worse. \\\\nIf that happens, call your doctor\\\\nright away or go directly to a hospital emergency room.\\\\nTell your doctor if yo...\",\"Sometimes, doctors will prescribe a medicine for a condition that is not written in the\\\\npatient information leaflets. Only use \\\\nNORVASC \\\\nthe way your doctor told you to. Do\\\\nnot give \\\\nNORVASC\\\\n to other people, even if they have the same symptoms you have. It\\\\nmay harm them.\\\\nYou can ask your pharmacist or doctor for information about \\\\nNORVASC\\\\n, or you can\\\\nvisit the Pfizer website at \\\\nwww.pfizer.com \\\\nor call 1-800-438-1985.\\\\nLAB-0015-10.0\\\\nRevised March 2017\\\\nPRINCIPAL DISPLAY PANEL - 2.5 mg Tablet Bot...\",\"(amlodipine besylate)\\\\ntablets\\\\n5 mg*\\\\n90 Tablets\\\\nRx only\\\\nPRINCIPAL DISPLAY PANEL - 5 mg Blister Pack\\\\nNorvasc\\\\n \\\\n(amlodipine besylate) Tablet\\\\n5 mg\\\\nPFIZER LABS\\\\nDIV OF PFIZER INC, NY, NY 10017\\\\nEXP &amp; LOT AREA\\\\n\\\\u00ae\",\"PRINCIPAL DISPLAY PANEL - 5 mg Blister Pack Box\\\\nUNIT DOSE\\\\nNDC 0069-1530-41\\\\nPfizer\\\\nNorvasc\\\\n \\\\n(amlodipine besylate)\\\\ntablets\\\\n5 mg *\\\\nFor in-institution use only\\\\n100 Tablets\\\\nRx only\\\\n\\\\u00ae\",\"PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label\\\\nNDC 0069-1540-68\\\\nPfizer\\\\nNorvasc \\\\n \\\\n(amlodipine besylate)\\\\ntablets\\\\n10 mg*\\\\n90 Tablets\\\\nRx only\\\\n\\\\u00ae\",\"PRINCIPAL DISPLAY PANEL - 10 mg Blister Pack\\\\nNorvasc\\\\n \\\\n(amlodipine besylate) Tablet\\\\n10 mg\\\\nPFIZER LABS\\\\nDIV OF PFIZER INC, NY, NY 10017\\\\nEXP &amp; LOT AREA\\\\n\\\\u00ae\",\"PRINCIPAL DISPLAY PANEL - 10 mg Blister Pack Box\\\\nUNIT DOSE\\\\nNDC 0069-1540-41\\\\nPfizer\\\\nNorvasc\\\\n \\\\n(amlodipine besylate)\\\\ntablets\\\\n10 mg *\\\\nFor in-institution use only\\\\n100 Tablets\\\\nRx only\\\\n\\\\u00ae\",\"NORVASC  \\\\namlodipine besylate tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:0069-1520\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nAMLODIPINE BESYLATE\\\\n (UNII: 864V2Q084H) \\\\n(AMLODIPINE - UNII:1J444QC288)\\\\nAMLODIPINE\\\\n2.5 mg\",\"Inactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nSODIUM STARCH GLYCOLATE TYPE A POTATO\\\\n (UNII: 5856J3G2A2)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE\\\\nScore\\\\nno score\\\\nShape\\\\nDIAMOND\\\\nSize\\\\n7mm\\\\nFlavor\\\\nImprint Code\\\\nNORVASC;2;5\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0069-1520-\\\\n68\\\\n90 \\\\nin 1 BOTTLE; Type 0:...\",\"MAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE\\\\nScore\\\\nno score\\\\nShape\\\\nOCTAGON (8 SIDED) (elongated octagon)\\\\nSize\\\\n9mm\\\\nFlavor\\\\nImprint Code\\\\nNORVASC;5\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0069-1530-\\\\n68\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n07/31/1992\\\\n07/31/2027\\\\n2\\\\nNDC:0069-1530-\\\\n41\\\\n100 \\\\nin 1 BOX, UNIT-DOSE\\\\n07/31/1992\\\\n09/30/2025\\\\n2\\\\n1 \\\\nin 1 BLISTER PACK; Type 0: Not a Combination\\\\nProduct\\\\n3\\\\nNDC:0069-...\",\"PFIZER LABORATORIES DIV PFIZER INC\\\\nProduct Characteristics\\\\nColor\\\\nWHITE\\\\nScore\\\\nno score\\\\nShape\\\\nROUND\\\\nSize\\\\n10mm\\\\nFlavor\\\\nImprint Code\\\\nNORVASC;10\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:0069-1540-\\\\n68\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n07/31/1992\\\\n10/31/2027\\\\n2\\\\nNDC:0069-1540-\\\\n41\\\\n100 \\\\nin 1 BOX, UNIT-DOSE\\\\n07/31/1992\\\\n02/28/2025\\\\n2\\\\n1 \\\\nin 1 BLISTER PACK; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplic...\",\"LOPRESSOR- metoprolol tartrate tablet \\\\n \\\\nValidus Pharmaceuticals LLC\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use \\\\nLOPRESSOR\\\\n safely and\\\\neffectively. See full prescribing information for \\\\nLOPRESSOR\\\\n. \\\\n      \\\\n \\\\nLOPRESSOR\\\\n (metoprolol \\\\ntart\\\\nr\\\\nate\\\\n) \\\\nt\\\\nablet\\\\ns\\\\n,\\\\n for \\\\no\\\\nral \\\\nu\\\\nse\\\\n \\\\nInitial U.S. Approval: \\\\n1992\\\\n \\\\nINDICATIONS AND USAGE\\\\nLOPRESSOR is a beta-adrenergic blocker indicated for the treatment of:\\\\nHypertension, to lower blo...\",\"CYP2D6 Inhibitors are likely to increase metoprolol concentration. (\\\\n7.3\\\\n)\\\\nConcomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase\\\\nthe risk of bradycardia. (\\\\n7.4\\\\n)\\\\nBeta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the\\\\nwithdrawal of clonidine. (\\\\n7.4\\\\n)\\\\nUSE IN SPECIFIC POPULATIONS\\\\nHepatic Impairment: Consider initiating LOPRESSOR therapy at low doses and gradually increase\\\\ndosage to optimize therapy, while monit...\",\"8.6 \\\\n  \\\\nHepatic Impairment\\\\n8.7 \\\\n  \\\\nRenal Impairment\\\\n10 \\\\n     \\\\nOVERDOSAGE\\\\n11 \\\\n     \\\\nDESCRIPTION\\\\n12 \\\\n      \\\\nCLINICAL PHARMACOLOGY\\\\n12.1 \\\\n   \\\\nMechanism of Action\\\\n12.2 \\\\n  \\\\nPharmacodynamics\\\\n12.3 \\\\n  \\\\nPharmacokinetics\\\\n12.5 \\\\n  \\\\nPharmacogenomics\\\\n13 \\\\n     \\\\nNONCLINICAL TOXICOLOGY\\\\n13.1 \\\\n  \\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 \\\\n     \\\\nCLINICAL STUDIES\\\\n14.1 \\\\n  \\\\nHypertension\\\\n14.2 \\\\n  \\\\nAngina Pectoris\\\\n14.3 \\\\n  \\\\nMyocardial Infarction\\\\n16 \\\\n     \\\\nHOW SUPPLIED/STORAGE AND HANDLING\\\\n17 \\\\n     \\\\nPATIENT CO...\",\"absolute risk increase per mmHg is greater at higher blood pressures, so that even\\\\nmodest reductions of severe hypertension can provide substantial benefit. Relative risk\\\\nreduction from blood pressure reduction is similar across populations with varying\\\\nabsolute risk, so the absolute benefit is greater in patients who are at higher risk\\\\nindependent of their hypertension (for example, patients with diabetes or\\\\nhyperlipidemia), and such patients would be expected to benefit from more aggressive\\\\ntr...\",\"been studied. If treatment is to be discontinued, reduce the dosage gradually over a\\\\nperiod of 1 - 2 weeks \\\\n[see \\\\nWarnings and Precautions (\\\\n5.1\\\\n)\\\\n].\\\\n2.3 \\\\n  \\\\nMyocardial Infarction\\\\nSee prescribing information of intravenous metoprolol for dosage instructions for\\\\nintravenous therapy.\\\\nIn patients who tolerate the full intravenous dose, initiate Lopressor tablets, 50 mg every\\\\n6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for\\\\n48 hours. In the case of intolerance, redu...\",\"dose of LOPRESSOR \\\\n[see \\\\nDosage and Administration (\\\\n2\\\\n)].\\\\n \\\\nIt may be necessary to lower\\\\nthe dose of LOPRESSOR or temporarily discontinue it. Such episodes do not preclude\\\\nsubsequent successful titration of LOPRESSOR.\\\\n5.3 \\\\n  \\\\nBronchospastic Disease\\\\nPatients with bronchospastic disease, should in general, not receive beta-blockers,\\\\nincluding Lopressor. Because of its relative beta\\\\n cardio-selectivity, however,\\\\nLOPRESSOR may be used in patients with bronchospastic disease who do not respond\\\\nto, o...\",\"5.\\\\n9\\\\n \\\\n  \\\\nPeripheral Vascular Disease\\\\nBeta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients\\\\nwith peripheral vascular disease.\\\\n6 \\\\n     \\\\nADVERSE REACTIONS\\\\nThe following adverse reactions are described elsewhere in labeling:\\\\nWorsening angina or myocardial infarction \\\\n[see \\\\nWarnings and Precautions (\\\\n5\\\\n)]\\\\n \\\\n \\\\nWorsening heart failure \\\\n[see \\\\nWarnings and Precautions (\\\\n5\\\\n)\\\\n]\\\\n.\\\\n \\\\nWorsening AV block \\\\n[see \\\\nContraindications (\\\\n4\\\\n)\\\\n]\\\\n.\\\\n6.1 \\\\n  \\\\nClinical Trials Experience\\\\n...\",\"Lopressor\\\\nPlacebo\\\\nHypotension (systolic BP &lt; 90 mm\\\\nHg)\\\\n27.4%\\\\n23.2%\\\\nBradycardia (heart rate &lt;\\\\n40 beats/min)\\\\n15.9%\\\\n6.7%\\\\nSecond- or third-degree heart block\\\\n4.7%\\\\n4.7%\\\\nFirst-degree heart block (P-R \\\\u2265\\\\n0.26 sec)\\\\n5.3%\\\\n1.9%\\\\nHeart failure\\\\n27.5%\\\\n29.6%\\\\n6.2 \\\\n  \\\\nPost-Marketing Experience\\\\nThe following adverse reactions have been identified during post approval use of\\\\nLOPRESSOR. Because these reactions are reported voluntarily from a population of\\\\nuncertain size, it is not always possible to reliably estimate...\",\"and propafenone were shown to double metoprolol concentrations. While there is no\\\\ninformation about moderate or weak inhibitors, these too are likely to increase\\\\nmetoprolol concentration. Increases in plasma concentration decrease the\\\\ncardioselectivity of metoprolol \\\\n[see Clinical Pharmacology (\\\\n12.3\\\\n)]. \\\\nMonitor patients\\\\nclosely, when the combination cannot be avoided.\\\\n7.\\\\n4\\\\n \\\\n  \\\\nNegative Chronotropes\\\\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction\\\\nand d...\",\"Data\\\\nHuman Data\\\\nData from published observational studies did not demonstrate an association of major\\\\ncongenital malformations and use of metoprolol in pregnancy. The published literature\\\\nhas reported inconsistent findings of intrauterine growth retardation, preterm birth and\\\\nperinatal mortality with maternal use of metoprolol during pregnancy; however, these\\\\nstudies have methodological limitations hindering interpretation. Methodological\\\\nlimitations include retrospective design, concomitant use...\",\"(range 17.0 to 158.7). The average relative infant dosage was 0.5% of the mother&#x27;s\\\\nweight-adjusted dosage.\\\\n8.\\\\n3 \\\\n \\\\nFemales and Males of Reproductive Potential\\\\nRisk Summary\\\\nBased on the published literature, beta-blockers (including metoprolol) may cause\\\\nerectile dysfunction and inhibit sperm motility. In animal fertility studies, metoprolol has\\\\nbeen associated with reversible adverse effects on spermatogenesis starting at oral\\\\ndose level of 3.5 mg/kg in rats, which would correspond to a dose of ...\",\"Signs and Symptoms - Overdosage of LOPRESSOR may lead to severe bradycardia,\\\\nhypotension, and cardiogenic shock. Clinical presentation can also include:\\\\natrioventricular block, heart failure, bronchospasm, hypoxia, impairment of\\\\nconsciousness/coma, nausea and vomiting.\\\\nTreatment \\\\u2013 Consider treating the patient with intensive care. Patients with myocardial\\\\ninfarction or heart failure may be prone to significant hemodynamic instability. Beta-\\\\nblocker overdose may result in significant resistance t...\",\"Metoprolol is a beta\\\\n-selective (cardioselective) adrenergic receptor blocking agent. This\\\\npreferential effect is not absolute, however, and at higher plasma concentrations,\\\\nmetoprolol also inhibits beta\\\\n-adrenoreceptors, chiefly located in the bronchial and\\\\nvascular musculature.\\\\nMetoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is\\\\ndetectable only at plasma concentrations much greater than required for beta-blockade.\\\\nAnimal and human experiments indicate tha...\",\"the ratio of approximately 2.5:1.\\\\nThere is a linear relationship between the log of plasma levels and reduction of exercise\\\\nheart rate. \\\\nHowever, antihypertensive activity does not appear to be related to plasma\\\\nlevels. Because of variable plasma levels attained with a given dose and lack of a\\\\nconsistent relationship of antihypertensive activity to dose, selection of proper dosage\\\\nrequires individual titration.\\\\nIn several studies of patients with acute myocardial infarction, intravenous followed...\",\"Renal\\\\n \\\\nimpairment\\\\n: The systemic availability and half-life of Lopressor in patients with\\\\nrenal failure do not differ to a clinically significant degree from those in normal subjects.\\\\nHepatic Impairment:\\\\n Since the drug is primarily eliminated by hepatic metabolism,\\\\nhepatic impairment may impact the pharmacokinetics of metoprolol.\\\\nDrug Interactions\\\\nMetoprolol is metabolized predominantly by CYP2D6. In healthy subjects with CYP2D6\\\\nextensive metabolizer phenotype, coadministration of quinidine 10...\",\"mg in a 60-kg patient.\\\\n14 \\\\n     \\\\nCLINICAL STUDIES\\\\n14.1 \\\\n  \\\\nHypertension\\\\nIn controlled clinical studies, Lopressor has been shown to be an effective\\\\nantihypertensive agent when used alone or as concomitant therapy with thiazide-type\\\\ndiuretics, at dosages of 100 mg to 450 mg daily. In controlled, comparative, clinical\\\\nstudies, Lopressor has been shown to be as effective an antihypertensive agent as\\\\npropranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and\\\\nstanding...\",\"however, it is also reasonable to administer the drug orally to patients at a later time as\\\\nis recommended for certain other beta-blockers.\\\\n16 \\\\n     \\\\nHOW SUPPLIED/STORAGE AND HANDLING\\\\nLopressor \\\\n(\\\\nmetoprolol tartrate\\\\n)\\\\n \\\\nt\\\\nablets\\\\nTablets 50 mg \\\\n\\\\u2013 capsule-shaped, biconvex, pink, scored (imprinted LOPRESSOR on\\\\none side and 458 twice on the scored side)\\\\n      \\\\nBottles of 100\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026\\\\u2026.\\\\u2026\\\\u2026\\\\u2026NDC 30698-458-01\\\\nTablets 100 mg \\\\n\\\\u2013 capsule-shaped, biconvex, light blue, scored (imprinted LOPRESSOR\\\\non on...\",\"NDC 30698-458-01\\\\nLopressor\\\\n(metoprolol tartrate USP) Tablets\\\\n50 mg\\\\n100 Tablets\\\\nRx Only\\\\nPRINCIPAL DISPLAY PANEL\\\\nNDC 30698-459-01\\\\nLopressor\\\\n(metoprolol tartrate USP) Tablets\\\\n100 mg\\\\n100 Tablets\\\\nRx Only\\\\nLOPRESSOR  \\\\nmetoprolol tartrate tablet\\\\nProduct Information\",\"Product Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:30698-458\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nMETOPROLOL TARTRATE\\\\n (UNII: W5S57Y3A5L) \\\\n(METOPROLOL -\\\\nUNII:GEB06NHM23)\\\\nMETOPROLOL\\\\nTARTRATE\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nD&amp;C RED NO. 30\\\\n (UNII: 2S42T2808B)\\\\n \\\\nLACTOSE, UNSPECIFIED FORM\\\\n (UNII: J2B2A4N98G)\\\\n \\\\nMAGNESIUM...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:30698-459\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nMETOPROLOL TARTRATE\\\\n (UNII: W5S57Y3A5L) \\\\n(METOPROLOL -\\\\nUNII:GEB06NHM23)\\\\nMETOPROLOL\\\\nTARTRATE\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nFD&amp;C BLUE NO. 2\\\\n (UNII: L06K8R7DQK)\\\\n \\\\nLACTOSE, UNSPECIFIED FORM\\\\n (UNII: J...\",\"Validus Pharmaceuticals LLC\\\\n \\\\nRevised: 9/2023\",\"ALBUTEROL SULFATE- albuterol sulfate solution \\\\n \\\\nIngenus Pharmaceuticals, LLC\\\\n----------\\\\nAlbuterol Sulfate Inhalation Solution \\\\n0.63 mg*/3 mL and 1.25 mg*/3 mL \\\\n(*Equivalent to 0.75 mg of albuterol sulfate or 1.5 mg of albuterol sulfate per\\\\n3 mL)\\\\nPRESCRIBING INFORMATION\\\\nDESCRIPTION\\\\nAlbuterol sulfate inhalation solution is a sterile, clear, colorless solution of the sulfate salt\\\\nof racemic albuterol, albuterol sulfate. Albuterol sulfate is a relatively selective beta \\\\n-\\\\nadrenergic bronchodilator ...\",\"ADMINISTRATION\\\\n).\\\\nCLINICAL PHARMACOLOGY\\\\nThe prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme\\\\nwhich catalyzes the formation of cyclic-3&#x27;,5&#x27;-adenosine monophosphate (cyclic AMP)\\\\nfrom adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular\\\\nresponses. In vitro studies and in vivo pharmacologic studies have demonstrated that\\\\nalbuterol has a preferential effect on beta \\\\n\\\\u2013adrenergic receptors compared with\\\\nisoproterenol. While it is recognized that...\",\"medication.\\\\nEfficacy, as measured by the mean percent change from baseline in the area under the\\\\n6-hour curve for FEV \\\\n, was demonstrated for both active treatment regimens (n=112\\\\n[1.25 mg group] and n=110 [0.63 mg group]) compared with placebo (n=110) on day 1\\\\nand day 28. Figures 1 and 2 illustrate the mean percentage change from pre-dose FEV\\\\non day 1 and day 28, respectively. The mean baseline FEV \\\\nfor all patients was 1.49 L.\\\\nFigure 1 \\\\n% Change from Pre-Dose FEV \\\\nIntent-to-Treat Population Da...\",\"The onset of a 15% increase in FEV \\\\nover baseline for both doses of albuterol sulfate\\\\ninhalation solution was seen at 30 minutes (the first post-dose assessment). The mean\\\\ntime to peak effect was approximately 30 to 60 minutes for both doses on day 1 and\\\\nafter 4 weeks of treatment. The mean duration of effect, as measured by a &gt;15%\\\\nincrease from baseline in FEV \\\\n, was approximately 2.5 hours for both doses on day 1\\\\nand approximately 2 hours for both doses after 4 weeks of treatment. In some pati...\",\"Deterioration of Asthma:\\\\nAsthma may deteriorate acutely over a period of hours or\\\\nchronically over several days or longer. If the patient needs more doses of albuterol\\\\nsulfate inhalation solution than usual, this may be a marker of destabilization of asthma\\\\nand requires re-evaluation of the patient and the treatment regimen, giving special\\\\nconsideration of the possible need for anti-inflammatory treatment (e.g.,\\\\ncorticosteroids).\\\\nFatalities have been reported in association with excessive use of...\",\"sulfate inhalation solution, when mixed with other drugs in a nebulizer, has not been\\\\nestablished.\\\\nSee illustrated Patient&#x27;s Instructions for Use.\\\\nDrug Interactions:\\\\nOther short-acting sympathomimetic aerosol bronchodilators or\\\\nepinephrine should not be used concomitantly with albuterol sulfate inhalation solution.\\\\nAlbuterol sulfate inhalation solution should be administered with extreme caution to\\\\npatients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or\\\\nwithin 2 ...\",\"of albuterol sulfate up to 50 mg/kg (approximately 30 times the maximum\\\\nrecommended daily inhalation dose of albuterol sulfate inhalation solution on a mg/m\\\\nbasis).\\\\nPregnancy:\\\\nTeratogenic Effects: Albuterol has been shown to be teratogenic in mice. A\\\\nstudy in CD-1 mice given albuterol subcutaneously showed cleft palate formation in 5 of\\\\n111 (4.5%) fetuses at 0.25 mg/kg (less than the maximum recommended daily\\\\ninhalation dose of albuterol sulfate inhalation solution on a mg/m \\\\nbasis) and cleft pa...\",\"solution in children age 6 to 12 years and published reports of albuterol sulfate trials in\\\\npediatric patients 3 years of age and older. The safety and effectiveness of albuterol\\\\nsulfate inhalation solution in children below 2 years of age have not been established.\\\\nADVERSE REACTIONS\\\\nClinical Trial Experience:\\\\nAdverse events reported in &gt;1% of patients receiving\\\\nalbuterol sulfate inhalation solution and more frequently than in patients receiving\\\\nplacebo in a four-week double-blind study are list...\",\"OVERDOSAGE\\\\nThe expected symptoms with overdosage are those of excessive beta-adrenergic\\\\nstimulation and/or occurrence or exaggeration of symptoms such as seizures, angina,\\\\nhypertension or hypotension, tachycardia with rates up to 200 beats per minute,\\\\narrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness,\\\\nfatigue, malaise, insomnia, and exaggeration of the pharmacological effects listed in\\\\nADVERSE REACTIONS. Hypokalemia may also occur. As with all sympathomimetic\\\\n...\",\"The safety and efficacy of albuterol sulfate inhalation solution have been established in\\\\nclinical trials when administered using the Pari LC Plus\\\\u2122 nebulizer and Pari PRONEB\\\\u2122\\\\ncompressor. The safety and efficacy of albuterol sulfate inhalation solution when\\\\nadministered with other nebulizer systems have not been established.\\\\nAlbuterol sulfate inhalation solution should be administered via jet nebulizer connected to\\\\nan air compressor with adequate air flow, equipped with a mouthpiece or suitable f...\",\"SPL PATIENT PACKAGE INSERT\\\\nPatient Information\\\\n \\\\nAlbuterol Sulfate Inhalation Solution\\\\n \\\\n(al bue&#x27; ter ol sul&#x27; fate)\\\\n \\\\n0.63 mg*/3 mL and 1.25 mg*/3 mL\\\\n \\\\n(*Equivalent to 0.75 mg of albuterol sulfate or 1.5 mg of albuterol sulfate per 3\\\\nmL)\\\\nRead the patient information that comes with albuterol sulfate inhalation\\\\nsolution before using it and each time you get a refill for your child. There may\\\\nbe new information. This leaflet does not take the place of talking to your\\\\nchild&#x27;s doctor about your chil...\",\"Keep the instructions with albuterol sulfate inhalation solution because you may want to\\\\nread them again. \\\\n\\\\u25cf \\\\nGive albuterol sulfate inhalation solution exactly as prescribed for your child. Do not\\\\nchange your child&#x27;s dose or how often it is used without talking to your child&#x27;s doctor first.\\\\n\\\\u25cf \\\\nAlbuterol sulfate inhalation solution is breathed into the lungs. Albuterol sulfate\\\\ninhalation solution is used with a special breathing machine called a nebulizer. Do not mix\\\\nother medicines with albuter...\",\"child&#x27;s doctor or pharmacist for information about albuterol sulfate inhalation solution that\\\\nis written for health professionals. You can also call Ingenus Pharmaceuticals, LLC toll free\\\\nat 1-877-748-1970.\\\\nWhat are the ingredients in albuterol sulfate inhalation solution?\\\\n \\\\nActive Ingredient:\\\\nalbuterol sulfate \\\\nInactive Ingredients:\\\\nsodium chloride and sulfuric acid\\\\nRx only\\\\n \\\\nManufactured for:\\\\n \\\\nIngenus Pharmaceuticals, LLC\\\\nOrlando, FL 32811-7193 \\\\nMade in China \\\\nRevised: 08/2024\\\\nINSTRUCTIONS FO...\",\"3. Connect the nebulizer to the mouthpiece or face mask (Figure 2).\\\\n4. Connect the nebulizer to the compressor. \\\\n5. Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or\\\\nput on the face mask (Figure 4); and turn on the compressor.\\\\n6. Breathe as calmly, deeply and evenly as possible through your mouth until no more\\\\nmist is formed in the nebulizer chamber (about 5-15 minutes). At this point, the treatment\\\\nis finished. \\\\n7. Clean the nebulizer (see manufacturer&#x27;s i...\",\"0.042% (1.25 mg/3 mL) - Pouch Labeling (5 vials)\",\"0.021% (0.63 mg/3 mL) - Carton Labeling (25 vials)\",\"0.042% (1.25 mg/3 mL) - Carton Labeling (25 vials)\",\"ALBUTEROL SULFATE  \\\\nalbuterol sulfate solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:50742-392\\\\nRoute of Administration\\\\nRESPIRATORY (INHALATION)\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nALBUTEROL SULFATE\\\\n (UNII: 021SEF3731) \\\\n(ALBUTEROL - UNII:QF8SVZ843E)\\\\nALBUTEROL\\\\n0.63 mg  in 3 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nSODIUM CHLORIDE\\\\n (UNII: 451W47IQ8X)\\\\n \\\\nSULFURIC ACID\\\\n (UNII: O40UQP6WCF)\\\\n \\\\nPackaging\",\"#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:50742-392-\\\\n25\\\\n5 \\\\nin 1 CARTON\\\\n11/01/2024\\\\n1\\\\nNDC:50742-392-\\\\n05\\\\n5 \\\\nin 1 POUCH\\\\n1\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nANDA\\\\nANDA215571\\\\n11/01/2024\\\\nALBUTEROL SULFATE  \\\\nalbuterol sulfate solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:50742-393\\\\nRoute of A...\",\"Ingenus Pharmaceuticals, LLC\\\\nCategory\\\\nCitation\\\\nDate\\\\nDate\\\\nANDA\\\\nANDA215571\\\\n11/01/2024\\\\nLabeler - \\\\nIngenus Pharmaceuticals, LLC \\\\n(833250017)\\\\nRegistrant - \\\\nLexenpharm (Suzhou) Limited (544252490)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nLexenpharm\\\\n(Suzhou) Limited\\\\n544252490\\\\nanalysis(50742-392, 50742-393) , manufacture(50742-392, 50742-393) ,\\\\nlabel(50742-392, 50742-393) , pack(50742-392, 50742-393)\\\\n \\\\nRevised: 10/2024\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"ATOVAQUONE AND PROGUANIL HCL- atovaquone and proguanil\\\\nhydrochloride tablet, film coated \\\\n \\\\nA-S Medication Solutions\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use Atovaquone and\\\\nProguanil Hydrochloride safely and effectively. See full prescribing information for\\\\nAtovaquone and Proguanil Hydrochloride.\\\\nAtovaquone and Proguanil Hydrochloride tablets\\\\nInitial U.S. Approval: 2000\\\\nINDICATIONS AND USAGE\\\\nAtovaquone and Proguanil Hydroc...\",\"ADVERSE REACTIONS\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact Prasco Laboratories at 1-866-525-0688\\\\nor FDA at 1-800-FDA-1088 or \\\\nwww.fda.gov/medwatch.\\\\nDRUG INTERACTIONS\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nUSE IN SPECIFIC POPULATIONS\\\\nRenal impairment: contraindicated for prophylaxis of \\\\nP. falciparum\\\\n malaria in patients with severe renal\\\\nimpairment. (\\\\n8.6\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 10/2023\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n1.1 Prevention of Malaria\\\\n1.2 Treatmen...\",\"8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\n8.2 Lactation\\\\n8.4 Pediatric Use\\\\n8.5 Geriatric Use\\\\n8.6 Renal Impairment\\\\n8.7 Hepatic Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Prevention of \\\\nP. falciparum\\\\n Malaria\\\\n14.2 Treatment of Acute, Uncomp...\",\"Atovaquone and Proguanil Hydrochloride tablets may be crushed and mixed with\\\\ncondensed milk just prior to administration to patients who may have difficulty\\\\nswallowing tablets.\\\\n2.1 Prevention of Malaria\\\\nStart prophylactic treatment with Atovaquone and Proguanil Hydrochloride tablets 1 or 2\\\\ndays before entering a malaria-endemic area and continue daily during the stay and for 7\\\\ndays after return.\\\\nAdults\\\\nOne Atovaquone and Proguanil Hydrochloride tablet (adult strength = 250 mg\\\\natovaquone/100 mg p...\",\"5 WARNINGS AND PRECAUTIONS\\\\n5.1 Vomiting and Diarrhea\\\\nAbsorption of atovaquone may be reduced in patients with diarrhea or vomiting. If\\\\nAtovaquone and Proguanil Hydrochloride tablets are used in patients who are vomiting,\\\\nparasitemia should be closely monitored and the use of an antiemetic considered. \\\\n[See\\\\nDosage and Administration (\\\\n2\\\\n).]\\\\n Vomiting occurred in up to 19% of pediatric patients\\\\ngiven treatment doses of atovaquone and proguanil hydrochloride. In the controlled\\\\nclinical trials, 15.3...\",\"In 3 clinical trials (2 of which were placebo-controlled) 381 adults (mean age: 31 years)\\\\nreceived atovaquone and proguanil hydrochloride for the prophylaxis of malaria; the\\\\nmajority of adults were black (90%) and 79% were male. In a clinical trial for the\\\\nprophylaxis of malaria, 125 pediatric patients (mean age: 9 years) received atovaquone\\\\nand proguanil hydrochloride; all subjects were black and 52% were male. Adverse\\\\nexperiences reported in adults and pediatric patients considered attributabl...\",\"Adverse experiences that started while receiving active study drug.\\\\n  Mean duration of dosing based on recommended dosing regimens.\\\\nExperience\\\\n(28 days)\\\\n(53 days)\\\\n(26 days)\\\\n(49 days)\\\\n   Diarrhea\\\\n38\\\\n(8)\\\\n36\\\\n(7)\\\\n34\\\\n(5)\\\\n39\\\\n(7)\\\\n   Nausea\\\\n14\\\\n(3)\\\\n20\\\\n(8)\\\\n11\\\\n(2)\\\\n18\\\\n(7)\\\\n   Abdominal pain\\\\n17\\\\n(5)\\\\n16\\\\n(5)\\\\n14\\\\n(3)\\\\n22\\\\n(6)\\\\n   Headache\\\\n12\\\\n(4)\\\\n17\\\\n(7)\\\\n12\\\\n(4)\\\\n14\\\\n(4)\\\\n   Dreams\\\\n7\\\\n(7)\\\\n16\\\\n(14)\\\\n6\\\\n(4)\\\\n7\\\\n(3)\\\\n   Insomnia\\\\n5\\\\n(3)\\\\n16\\\\n(13)\\\\n4\\\\n(2)\\\\n5\\\\n(2)\\\\n   Fever\\\\n9\\\\n(&lt;1)\\\\n11\\\\n(1)\\\\n8\\\\n(&lt;1)\\\\n8\\\\n(&lt;1)\\\\n   Dizziness\\\\n5\\\\n(2)\\\\n14\\\\n(9)\\\\n7\\\\n(3)\\\\n8\\\\n(4)\\\\n   V...\",\"In 2 controlled trials, 116 pediatric patients (weighing 11 to 40 kg) (mean age: 7 years)\\\\nreceived atovaquone and proguanil hydrochloride for the treatment of malaria. The\\\\nmajority of subjects were black (72%); 28% were of other racial/ethnic groups, primarily\\\\nAsian. Attributable adverse experiences that occurred in \\\\u22655% of patients were vomiting\\\\n(10%) and pruritus (6%). Vomiting occurred in 43 of 319 (13%) pediatric patients who\\\\ndid not have symptomatic malaria but were given treatment doses of ...\",\"Gastrointestinal Disorders\\\\nStomatitis.\\\\nHepatobiliary Disorders\\\\nElevated liver laboratory tests, hepatitis, cholestasis; hepatic failure requiring transplant\\\\nhas been reported.\\\\nSkin and Subcutaneous Tissue Disorders\\\\nPhotosensitivity, rash, erythema multiforme, and Stevens-Johnson syndrome.\\\\n7 DRUG INTERACTIONS\\\\n7.1 Rifampin/Rifabutin\\\\nConcomitant administration of rifampin or rifabutin is known to reduce atovaquone\\\\nconcentrations \\\\n[see Clinical Pharmacology (\\\\n12.3\\\\n)]\\\\n. The concomitant administration...\",\"8.1 Pregnancy\\\\nRisk Summary\\\\nAvailable data from published literature and postmarketing experience with use of\\\\natovaquone and proguanil hydrochloride in pregnant women are insufficient to identify a\\\\ndrug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal\\\\noutcomes\\\\n.\\\\n The proguanil component of Atovaquone and Proguanil Hydrochloride tablets\\\\nacts to inhibit parasitic dihydrofolate reductase; however, pregnant women and females\\\\nof reproductive potential should continue ...\",\"maternally toxic dose of 1,200 mg/kg/day corresponding to plasma exposures that were\\\\napproximately 1.3 times the estimated human exposure during treatment of malaria\\\\nbased on AUC. In a pre- and post-natal study in rats, atovaquone administered in oral\\\\ndoses of 250, 500, and 1,000 mg/kg/day from GD15 until Lactation Day (LD) 20 did not\\\\nimpair the growth or developmental effects in first generation offspring at doses up to\\\\n1,000 mg/kg/day corresponding to AUC exposures of approximately 7.3 times t...\",\"In a rat study with doses of 10 and 250 mg/kg, given orally by gavage on postpartum\\\\nDay 11, atovaquone concentrations in the milk were 30% of the concurrent atovaquone\\\\nconcentrations in the maternal plasma at both doses. The concentration of drug in\\\\nanimal milk does not necessarily predict the concentration of drug in human milk.\\\\n8.4 Pediatric Use\\\\nProphylaxis of Malaria\\\\nSafety and effectiveness have not been established in pediatric patients who weigh less\\\\nthan 11 kg. The efficacy and safety of ...\",\"patient who also took an unspecified dose of dapsone, methemoglobinemia occurred.\\\\nRash has also been reported after overdose.\\\\nOverdoses of proguanil hydrochloride as large as 1,500 mg have been followed by\\\\ncomplete recovery, and doses as high as 700 mg twice daily have been taken for over\\\\n2 weeks without serious toxicity. Adverse experiences occasionally associated with\\\\nproguanil hydrochloride doses of 100 to 200 mg/day, such as epigastric discomfort and\\\\nvomiting, would be likely to occur with o...\",\"Each Atovaquone and Proguanil Hydrochloride tablet (adult strength) contains 250 mg\\\\nof atovaquone and 100 mg of proguanil hydrochloride. The inactive ingredients are low-\\\\nsubstituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose,\\\\npoloxamer 188, povidone K30, and sodium starch glycolate. The tablet coating contains\\\\nhypromellose, polyethylene glycol 400, polyethylene glycol 8000, red iron oxide, and\\\\ntitanium dioxide.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nAtova...\",\"patients, but may be longer in individuals who are slow metabolizers.\\\\nThe main routes of elimination are hepatic biotransformation and renal excretion.\\\\nMetabolism:\\\\n In a study where \\\\nC\\\\u2011labeled atovaquone was administered to healthy\\\\nvolunteers, greater than 94% of the dose was recovered as unchanged atovaquone in\\\\nthe feces over 21 days. There was little or no excretion of atovaquone in the urine (less\\\\nthan 0.6%). There is indirect evidence that atovaquone may undergo limited metabolism;\\\\nhowever, ...\",\"elderly subjects (mean: 14.9 hours) compared with younger subjects (mean: 8.3 hours).\\\\nPatients with Renal Impairment:\\\\n In patients with mild renal impairment (creatinine\\\\nclearance 50 to 80 mL/min), oral clearance and/or AUC data for atovaquone, proguanil,\\\\nand cycloguanil are within the range of values observed in patients with normal renal\\\\nfunction (creatinine clearance &gt;80 mL/min). In patients with moderate renal impairment\\\\n(creatinine clearance 30 to 50 mL/min), mean oral clearance for proguan...\",\"Drug Interaction Studies\\\\nThere are no pharmacokinetic interactions between atovaquone and proguanil at the\\\\nrecommended dose.\\\\nAtovaquone is highly protein bound (&gt;99%) but does not displace other highly protein-\\\\nbound drugs in vitro.\\\\nProguanil is metabolized primarily by CYP2C19. Potential pharmacokinetic interactions\\\\nbetween proguanil or cycloguanil and other drugs that are CYP2C19 substrates or\\\\ninhibitors are unknown.\\\\nRifampin/Rifabutin:\\\\n Concomitant administration of rifampin or rifabutin is k...\",\"13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nGenotoxicity studies have not been performed with atovaquone in combination with\\\\nproguanil. Effects of atovaquone and proguanil hydrochloride on male and female\\\\nreproductive performance are unknown.\\\\nAtovaquone\\\\nA 24-month carcinogenicity study in CD rats was negative for neoplasms at doses up to\\\\n500 mg/kg/day corresponding to approximately 54 times the average steady-state\\\\nplasma concentrations in humans during pr...\",\"13.2 Animal Toxicology and/or Pharmacology\\\\nFibrovascular proliferation in the right atrium, pyelonephritis, bone marrow\\\\nhypocellularity, lymphoid atrophy, and gastritis/enteritis were observed in dogs treated\\\\nwith proguanil hydrochloride for 6 months at a dose of 12 mg/kg/day (approximately\\\\n3.9 times the recommended daily human dose for malaria prophylaxis on a mg/m\\\\nbasis). Bile duct hyperplasia, gall bladder mucosal atrophy, and interstitial pneumonia\\\\nwere observed in dogs treated with proguani...\",\"placebo withdrew from the study for reasons other than parasitemia (primary reason\\\\nwas lost to follow-up). One out of 150 evaluable patients (&lt;1%) who received\\\\natovaquone and proguanil hydrochloride developed \\\\nP. falciparum \\\\nparasitemia while\\\\nreceiving prophylaxis with atovaquone and proguanil hydrochloride compared with 31\\\\n(22%) of the 144 evaluable placebo recipients.\\\\nIn a 10\\\\u2011week study in 175 South African subjects who moved into malaria\\\\u2011endemic\\\\nareas and were given prophylaxis with 1 atovaqu...\",\"atovaquone 250 mg 24 hours prior to malaria challenge were protected from developing\\\\nmalaria, whereas all 4 placebo\\\\u2011treated patients developed malaria.\\\\nDuring the 4 weeks following cessation of prophylaxis in clinical trial participants who\\\\nremained in malaria-endemic areas and were available for evaluation, malaria developed\\\\nin 24 of 211 (11.4%) subjects who took placebo and 9 of 328 (2.7%) who took\\\\natovaquone and proguanil hydrochloride. While new infections could not be\\\\ndistinguished from rec...\",\"Atovaquone and proguanil hydrochloride = 1,000 mg atovaquone and 400 mg\\\\nproguanil hydrochloride (or equivalent based on body weight for patients weighing\\\\n\\\\u226440 kg) once daily for 3 days.\\\\n  Elimination of parasitemia with no recurrent parasitemia during follow\\\\u2011up for\\\\n28 days.\\\\n  Patients hospitalized only for acute care. Follow\\\\u2011up conducted in outpatients.\\\\n  Study in pediatric patients aged 3 to 12 years.\\\\nFrance\\\\n21\\\\n100.0%\\\\nHalofantrine\\\\n18\\\\n100.0%\\\\nKenya\\\\n81\\\\n93.8%\\\\nHalofantrine\\\\n83\\\\n90.4%\\\\nZambia\\\\n80\\\\n100.0%\\\\nP...\",\"Product: \\\\n50090-2980\\\\nNDC: \\\\n50090-2980-0 \\\\n7 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-1 \\\\n12 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-2 \\\\n14 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-3 \\\\n16 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-4 \\\\n24 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-5 \\\\n5 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-6 \\\\n10 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-7 \\\\n100 TABLET, FILM COATED in a BOTTLE\\\\nNDC: \\\\n50090-2980-8 \\\\n20 TABLET, FILM COAT...\",\"Mason, OH 45040 USA\\\\nAPH-PS:5PI\\\\nStorage\\\\nStore at 25oC (77oF); excursions permitted to 15o to 30oC (59o to 86oF) (see USP\\\\nControlled Room Temperature). Do not use if printed safety seal under cap is broken or\\\\nmissing.\\\\natovaquone and proguanil hydrochloride\\\\nATOVAQUONE AND PROGUANIL HCL  \\\\natovaquone and proguanil hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:50090-2980(NDC:66993-\\\\n060)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/A...\",\"MICROCRYSTALLINE CELLULOSE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 188\\\\n (UNII: LQA7B6G8JG)\\\\n \\\\nPOVIDONE K30\\\\n (UNII: U725QWY32X)\\\\n \\\\nSODIUM STARCH GLYCOLATE TYPE A POTATO\\\\n (UNII: 5856J3G2A2)\\\\n \\\\nHYPROMELLOSE, UNSPECIFIED\\\\n (UNII: 3NXW29V3WO)\\\\n \\\\nPOLYETHYLENE GLYCOL 400\\\\n (UNII: B697894SGQ)\\\\n \\\\nPOLYETHYLENE GLYCOL 8000\\\\n (UNII: Q662QK8M3B)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nPINK\\\\nScore\\\\nno score\\\\nShape\\\\nROUND\\\\nSize\\\\n11mm\\\\nFlavor\\\\nImprint Code\\\\nGX;CM3\\\\nCo...\",\"A-S Medication Solutions\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nA-S Medication Solutions\\\\n830016429\\\\nRELABEL(50090-2980) , REPACK(50090-2980)\\\\n \\\\nRevised: 10/2023\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#999\",\"#999\",\"#2ca02c\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#ffbb78\",\"#ffbb78\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#2ca02c\",\"#2ca02c\"],\"shape\":[165],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1292\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1293\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1288\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1289\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1290\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1259\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1274\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1275\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1276\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1277\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1278\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1283\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1284\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1269\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1270\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1271\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1272\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1264\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1265\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1266\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1267\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1268\",\"attributes\":{\"axis\":{\"id\":\"p1264\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1273\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1269\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1294\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1295\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Albuterol Inhalation Solution\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":112}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1296\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Amlodipine Side Effects\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":61}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1297\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Malaria Prophylaxis\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":139}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1298\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Metformin Hydrochloride\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":30}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1299\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Metoprolol Pharmacokinetics\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":91}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1300\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":6}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1301\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Pharmaceutical Ingredients\"},\"renderers\":[{\"id\":\"p1291\"}],\"index\":0}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1371\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1307\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1316\",\"attributes\":{\"start\":8.888234281539917,\"end\":24.644878578186034}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1317\",\"attributes\":{\"start\":-11.353830933570862,\"end\":-0.5755528211593628}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1318\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1319\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1314\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1346\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1303\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1304\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1305\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"CM9uQTU6MEF/9pFBC1qQQVphJEHvTH1BQs19QULockEA2mVB0YuOQQ==\"},\"shape\":[10],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"pJ8UwUh2XMCdM63AiuKOwCLNWMC+zRfA4i8JwfHr+sDUSQDBlJSJwA==\"},\"shape\":[10],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Ingredients\",\"Malaria Prophylaxis\",\"Amlodipine Side Effects\",\"Amlodipine Side Effects\",\"Malaria Prophylaxis\",\"Metoprolol Pharmacokinetics\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Pharmaceutical Ingredients\",\"Amlodipine Side Effects\"]],[\"correctness\",[true,true,true,true,true,true,false,true,false,false]],[\"questions\",[\"What are the directions for taking Advil Gel Caplets?\",\"What are the active ingredients in the atovaquone and proguanil hydrochloride tablet?\",\"What steps should be taken if there is a suspicion of having consumed an excessive amount of NORVASC, and what specific actions should be avoided in such a situation?\",\"What are the speculated mechanisms involved in amlodipine&#x27;s efficacy in alleviating exertional angina and vasospastic angina?\",\"Can you provide the chemical names of atovaquone and proguanil hydrochloride for pharmaceutical use?\",\"What is the estimated oral bioavailability of immediate release metoprolol for patients with heart disease, and what factor contributes to it being around 50%?\",\"Can you provide me with a list of the inactive ingredients present in Advil ibuprofen tablets? I am curious to know what substances are included in them.\",\"Before using this CERTUS PVP-1 PREP SWABSTICK on a minor cut, can you confirm if the active ingredient is Povidone-Iodine?\",\"What are the active and inactive ingredients in the medication?\",\"What can be observed?\"]],[\"agent_answer\",[\"The directions for taking Advil Gel Caplets are:\\\\n\\\\n- Adults and children 12 years and over: take 1 gel caplet every 4 to 6 hours while symptoms persist.  \\\\n- If pain or fever does not respond to 1 gel caplet, 2 gel caplets may be used.  \\\\n- Do not exceed 6 gel caplets in 24 hours, unless directed by a doctor.  \\\\n- Children under 12 years: ask a doctor.  \\\\n\\\\nAdditional warnings:  \\\\n- Do not take more than directed.  \\\\n- The smallest effective dose should be used.  \\\\n\\\\nThese instructions are based on the provided context from the Advil Gel Caplets documentation.\",\"The active ingredients in the Atovaquone and Proguanil Hydrochloride tablet (adult strength) are:  \\\\n- **Atovaquone**: 250 mg  \\\\n- **Proguanil Hydrochloride**: 100 mg  \\\\n\\\\n(Source: Context from the prescribing information document.)\",\"Based on the provided context, here are the steps to take if there is a suspicion of consuming too much NORVASC:  \\\\n\\\\n1. **Immediate Action**:  \\\\n   - Call your doctor or Poison Control Center right away.  \\\\n   - Go directly to the nearest hospital emergency room.  \\\\n\\\\n2. **What to Avoid**:  \\\\n   - Do not start any new prescription or non-prescription medicines or supplements without checking with your doctor first.  \\\\n\\\\nThe context does not mention any other specific actions to avoid, but the key steps are seeking medical help immediately and avoiding self-medication.\",\"Based on the provided context, the speculated mechanisms for amlodipine&#x27;s (NORVASC) efficacy in alleviating angina include:\\\\n\\\\n1. **Exertional Angina**:  \\\\n   - Reduces total peripheral resistance (afterload), decreasing the workload of the heart.  \\\\n   - Lowers the rate-pressure product, reducing myocardial oxygen demand during exercise.  \\\\n\\\\n2. **Vasospastic Angina**:  \\\\n   - Blocks constriction and restores blood flow in coronary arteries/arterioles in response to calcium, potassium, epinephrine, serotonin, and thromboxane A2 analog (observed in experimental models and *in vitro* human coronary vessels).  \\\\n\\\\nThe context does not provide further mechanistic details beyond these points. Let me know if you&#x27;d like clarification or additional supported information!\",\"The chemical name of atovaquone is *trans*-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione.  \\\\n\\\\nThe chemical name of proguanil hydrochloride is 1-(4-chlorophenyl)-5-isopropyl-biguanide hydrochloride.  \\\\n\\\\nBoth names are as specified in the pharmaceutical context provided.\",\"Based on the context, the estimated oral bioavailability of immediate-release metoprolol is about **50%** because of **pre-systemic metabolism**, which is saturable, leading to a non-proportionate increase in exposure with increased dose. This applies to patients with heart disease as well, as there is no mention of altered bioavailability specifically for this group in the provided context. \\\\n\\\\nThe primary factor contributing to the ~50% bioavailability is the pre-systemic (first-pass) metabolism.\",\"Based on the provided context, the inactive ingredients in **Advil ibuprofen tablets (200 mg)** are:  \\\\n\\\\n- **Croscarmellose Sodium**  \\\\n- **FD&amp;C Red No. 40**  \\\\n- **FD&amp;C Yellow No. 6**  \\\\n- **Ferric Oxide Red**  \\\\n- **Gelatin, Unspecified**  \\\\n- **Glycerin**  \\\\n- **Hypromellose, Unspecified**  \\\\n\\\\nThese ingredients are listed across multiple documents in the context, specifically under the **Inactive Ingredients** section for Advil (NDC:0573-0165 and NDC:0573-0166).  \\\\n\\\\nLet me know if you&#x27;d like further details about any of these ingredients!\",\"Based on the provided context, the active ingredient in CERTUS PVP-1 PREP SWABSTICK is **Povidone Iodine USP 10%** (equivalent to 1% titratable iodine).  \\\\n\\\\nYes, it contains Povidone-Iodine as the active ingredient.  \\\\n\\\\n(Source: Drug Facts Box OTC Active Ingredient Section from the label).\",\"No response\",\"No response\"]],[\"reference_answer\",[\"For Advil Gel Caplets, adults and children 12 years and over should take 1 gel caplet every 4 to 6 hours while symptoms persist. The smallest effective dose should be used. Do not exceed 6 gel caplets in 24 hours, unless directed by a doctor. Children under 12 years should ask a doctor before taking.\",\"The active ingredients in the atovaquone and proguanil hydrochloride tablet are Atovaquone (250 mg) and Proguanil Hydrochloride (100 mg).\",\"If you suspect you have taken too much NORVASC, you should call your doctor or Poison Control Center, or go to the nearest hospital emergency room right away.\",\"The precise mechanisms by which amlodipine relieves angina are not fully delineated, but are thought to include reducing total peripheral resistance (afterload), reducing the rate pressure product, and thus myocardial oxygen demand in exertional angina. In vasospastic angina, amlodipine blocks constriction and restores blood flow in coronary arteries and arterioles in response to various stimuli.\",\"The chemical name of atovaquone is trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione. The chemical name of proguanil hydrochloride is 1-(4-chlorophenyl)-5-isopropyl-biguanide hydrochloride.\",\"The estimated oral bioavailability of immediate release metoprolol is about 50% due to pre-systemic metabolism, which is saturable and leads to a non-proportionate increase in exposure with increased dose.\",\"The inactive ingredients in Advil ibuprofen tablets include microcrystalline cellulose, croscarmellose sodium, ferric oxide red, methylparaben, povidone, propylparaben, shellac, silicon dioxide, sodium benzoate, sodium lauryl sulfate, starch (corn), stearic acid, sucrose, titanium dioxide, white wax, and diacetylated monoglycerides.\",\"The active ingredient in CERTUS PVP-1 PREP SWABSTICK is Povidone-Iodine.\",\"The active ingredients in the medication are DEXBROMPHENIRAMINE MALEATE and PSEUDOEPHEDRINE HYDROCHLORIDE, while some of the inactive ingredients include CITRIC ACID MONOHYDRATE, GLYCERIN, MENTHOL, METHYLPARABEN, WATER, PROPYLENE GLYCOL, PROPYLPARABEN, SODIUM CITRATE, and SUCRALOSE.\",\"Some of the adverse reactions reported with an incidence greater than 1.0% in placebo-controlled clinical trials for NORVASC include fatigue, nausea, abdominal pain, and somnolence.\"]],[\"id\",[8,165,81,72,154,105,20,137,30,67]],[\"content\",[\"vomit blood\\\\nhave bloody or black stools\\\\nhave stomach pain that does not get better\\\\nyou have symptoms of heart problems or stroke:\\\\nchest pain\\\\ntrouble breathing\\\\nweakness in one part or side of body\\\\nslurred speech\\\\nleg swelling\\\\npain gets worse or lasts more than 10 days\\\\nfever gets worse or lasts more than 3 days\\\\nredness or swelling is present in the painful area\\\\nany new symptoms appear\\\\nIf pregnant or breast-feeding,\\\\nask a health professional before use. It is especially important not to use ibuprofe...\",\"Mason, OH 45040 USA\\\\nAPH-PS:5PI\\\\nStorage\\\\nStore at 25oC (77oF); excursions permitted to 15o to 30oC (59o to 86oF) (see USP\\\\nControlled Room Temperature). Do not use if printed safety seal under cap is broken or\\\\nmissing.\\\\natovaquone and proguanil hydrochloride\\\\nATOVAQUONE AND PROGUANIL HCL  \\\\natovaquone and proguanil hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:50090-2980(NDC:66993-\\\\n060)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/A...\",\"4.\\\\nHow should I take NORVASC?\\\\n1.\\\\n2.\\\\n3.\\\\n4.\\\\n5.\\\\n6.\\\\nWhat should I avoid while taking NORVASC?\\\\n1.\\\\nWhat are the possible side effects of NORVASC?\\\\nNORVASC \\\\nmay cause the following side effects. \\\\nMost side effects are mild or moderate:\\\\n1.\\\\n2.\\\\n3.\\\\n4.\\\\n5.\\\\n6.\\\\n7.\\\\n8.\\\\nIt is rare, but when you first start taking \\\\nNORVASC\\\\n or increase your dose, you may\\\\nhave a heart attack or your angina may get worse. \\\\nIf that happens, call your doctor\\\\nright away or go directly to a hospital emergency room.\\\\nTell your doctor if yo...\",\"can be detected \\\\nin vitro\\\\n but such effects have not been seen in intact animals at\\\\ntherapeutic doses. Serum calcium concentration is not affected by amlodipine. Within\\\\nthe physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic\\\\ninteraction with the calcium channel receptor is characterized by a gradual rate of\\\\nassociation and dissociation with the receptor binding site, resulting in a gradual onset of\\\\neffect.\\\\nAmlodipine is a peripheral arterial vasodilator that acts d...\",\"patient who also took an unspecified dose of dapsone, methemoglobinemia occurred.\\\\nRash has also been reported after overdose.\\\\nOverdoses of proguanil hydrochloride as large as 1,500 mg have been followed by\\\\ncomplete recovery, and doses as high as 700 mg twice daily have been taken for over\\\\n2 weeks without serious toxicity. Adverse experiences occasionally associated with\\\\nproguanil hydrochloride doses of 100 to 200 mg/day, such as epigastric discomfort and\\\\nvomiting, would be likely to occur with o...\",\"the ratio of approximately 2.5:1.\\\\nThere is a linear relationship between the log of plasma levels and reduction of exercise\\\\nheart rate. \\\\nHowever, antihypertensive activity does not appear to be related to plasma\\\\nlevels. Because of variable plasma levels attained with a given dose and lack of a\\\\nconsistent relationship of antihypertensive activity to dose, selection of proper dosage\\\\nrequires individual titration.\\\\nIn several studies of patients with acute myocardial infarction, intravenous followed...\",\"8\\\\n115 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA018989\\\\n05/18/1984\\\\nADVIL  \\\\nibuprofen tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:0573-0161\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nIBUPROFEN\\\\n (UNII: WK2XYI10QM) \\\\n(IBUPROFEN - UNII:WK2XYI10QM)\\\\nIBUPROFEN\\\\n200 mg\\\\nIna...\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Llorens Pharmaceutical International Division\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nDEXBROMPHENIRAMINE MALEATE\\\\n (UNII: BPA9UT29BS)\\\\n(DEXBROMPHENIRAMINE - UNII:75T64B71RP)\\\\nDEXBROMPHENIRAMINE\\\\nMALEATE\\\\n1 mg\\\\n in 5 mL\\\\nPSEUDOEPHEDRINE HYDROCHLORIDE\\\\n (UNII: 6V9V2RYJ8N)\\\\n(PSEUDOEPHEDRINE - UNII:7CUC9DDI9F)\\\\nPSEUDOEPHEDRINE\\\\nHYDROCHLORIDE\\\\n30 mg\\\\n in 5 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\n...\",\"Other adverse reactions that were not clearly dose related but were reported with an\\\\nincidence greater than 1.0% in placebo-controlled clinical trials include the following:\\\\nNORVASC (%)\\\\nPlacebo (%)\\\\n(N=1730)\\\\n(N=1250)\\\\nFatigue\\\\n4.5\\\\n2.8\\\\nNausea\\\\n2.9\\\\n1.9\\\\nAbdominal Pain\\\\n1.6\\\\n0.3\\\\nSomnolence\\\\n1.4\\\\n0.6\\\\nFor several adverse experiences that appear to be drug and dose related, there was a\\\\ngreater incidence in women than men associated with amlodipine treatment as shown in\\\\nthe following table:\\\\nNORVASC\\\\nPlacebo\\\\nMale...\"]],[\"color\",[\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1347\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1348\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1343\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1344\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1345\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1361\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1352\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1353\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1354\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[165],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[165],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1362\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1363\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1358\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1359\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1360\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1315\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1330\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1331\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1332\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1333\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1338\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1339\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1306\",\"attributes\":{\"renderers\":[{\"id\":\"p1346\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1325\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1326\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1327\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1328\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1320\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1321\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1322\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1323\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1324\",\"attributes\":{\"axis\":{\"id\":\"p1320\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1329\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1325\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1349\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1350\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1346\"}],\"index\":6}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1351\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1346\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1367\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1364\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1365\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1366\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Po8hQZ9YgkG/Yl5BgtVEQWRsd0FUI45B\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"PSlSwErLOMBSX4rALN7ewE/3/MAboKPA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Malaria Prophylaxis\",\"Metoprolol Pharmacokinetics\",\"Metformin Hydrochloride\",\"Albuterol Inhalation Solution\",\"Pharmaceutical Ingredients\",\"Amlodipine Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"7949a191-3357-4b24-8b04-061d301649b2\",\"roots\":{\"p1372\":\"c5fb80f1-43cc-47f9-bcc8-d8be0546102e\"},\"root_ids\":[\"p1372\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"c5fb80f1-43cc-47f9-bcc8-d8be0546102e\" data-root-id=\"p1372\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x7dbd63d4ec60>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from giskard.rag import evaluate\n",
    "\n",
    "report = evaluate(answer_fn, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "report.to_html(\"report.html\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>correctness</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>question_type</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>complex</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>conversational</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>distracting element</th>\n",
       "      <td>0.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>double</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>simple</th>\n",
       "      <td>0.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>situational</th>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     correctness\n",
       "question_type                   \n",
       "complex                      0.0\n",
       "conversational               0.0\n",
       "distracting element          0.5\n",
       "double                       0.0\n",
       "simple                       0.5\n",
       "situational                  0.0"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.correctness_by_question_type()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>reference_answer</th>\n",
       "      <th>reference_context</th>\n",
       "      <th>conversation_history</th>\n",
       "      <th>metadata</th>\n",
       "      <th>agent_answer</th>\n",
       "      <th>correctness</th>\n",
       "      <th>correctness_reason</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>id</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>76e4e628-e8be-4675-a04e-1208c39eb612</th>\n",
       "      <td>What is the strength of ALBUTEROL SULFATE in t...</td>\n",
       "      <td>The strength of ALBUTEROL SULFATE in the solut...</td>\n",
       "      <td>Document 215: ALBUTEROL SULFATE  \\nalbuterol s...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'simple', 'seed_document_id'...</td>\n",
       "      <td>The ALBUTEROL SULFATE inhalation solution is a...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional information abou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3a0b5032-84e3-405d-a8c9-43d62cd79c3c</th>\n",
       "      <td>What are the recommended precautions to be tak...</td>\n",
       "      <td>When discontinuing therapy with Lopressor, par...</td>\n",
       "      <td>Document 181: been studied. If treatment is to...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>The document highlights the following precauti...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional information abou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2e22dd3f-eae2-446f-a07b-5410126788cd</th>\n",
       "      <td>What adverse reactions have been reported duri...</td>\n",
       "      <td>The adverse reactions identified during post a...</td>\n",
       "      <td>Document 184: Lopressor\\nPlacebo\\nHypotension ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Here are the adverse reactions reported during...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided some adverse reactions repo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73e18ef5-254e-44e7-9171-26ca90d40210</th>\n",
       "      <td>Can you provide the list of inactive ingredien...</td>\n",
       "      <td>The inactive ingredients in Lipitor 40mg table...</td>\n",
       "      <td>Document 114: CALCIUM CARBONATE\\n (UNII: H0G93...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'distracting element', 'seed...</td>\n",
       "      <td>Based on the provided document, I can share th...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided the inactive ingredients fo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7cd4bf5b-e8b5-412d-9015-7fc4967b63d2</th>\n",
       "      <td>Can you please confirm the active ingredient a...</td>\n",
       "      <td>The active ingredient in the ALBUTEROL SULFATE...</td>\n",
       "      <td>Document 216: #\\nItem Code\\nPackage Descriptio...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'situational', 'seed_documen...</td>\n",
       "      <td>The active ingredient in the **Albuterol Sulfa...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent stated that the strength of the Albu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba</th>\n",
       "      <td>What are some of the risk factors for developi...</td>\n",
       "      <td>Risk factors for myopathy associated with LIPI...</td>\n",
       "      <td>Document 78: Select Azole Antifungals or Macro...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'situational', 'seed_documen...</td>\n",
       "      <td>Based on the provided context, here are key ri...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed information about ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92d517b2-54d4-44ce-a923-08c44e3c6ed3</th>\n",
       "      <td>What instructions should patients be given whe...</td>\n",
       "      <td>Patients should be instructed to take a repeat...</td>\n",
       "      <td>Document 361: Product: \\n50090-2980\\nNDC: \\n50...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'double', 'original_question...</td>\n",
       "      <td>Here are the key instructions patients should ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional instructions for...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>c940d678-3141-4420-b01d-6ab2179e11d3</th>\n",
       "      <td>What should be done?</td>\n",
       "      <td>Patients prescribed ZOLOFT oral solution shoul...</td>\n",
       "      <td>Document 320: Suicidal Thoughts and Behaviors\\...</td>\n",
       "      <td>[{'role': 'user', 'content': 'Patients prescri...</td>\n",
       "      <td>{'question_type': 'conversational', 'seed_docu...</td>\n",
       "      <td>The provided document snippet lists pharmaceut...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a general response about ph...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                               question  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  What is the strength of ALBUTEROL SULFATE in t...   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  What are the recommended precautions to be tak...   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  What adverse reactions have been reported duri...   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  Can you provide the list of inactive ingredien...   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  Can you please confirm the active ingredient a...   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  What are some of the risk factors for developi...   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  What instructions should patients be given whe...   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3                               What should be done?   \n",
       "\n",
       "                                                                       reference_answer  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  The strength of ALBUTEROL SULFATE in the solut...   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  When discontinuing therapy with Lopressor, par...   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  The adverse reactions identified during post a...   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  The inactive ingredients in Lipitor 40mg table...   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  The active ingredient in the ALBUTEROL SULFATE...   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  Risk factors for myopathy associated with LIPI...   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  Patients should be instructed to take a repeat...   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  Patients prescribed ZOLOFT oral solution shoul...   \n",
       "\n",
       "                                                                      reference_context  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  Document 215: ALBUTEROL SULFATE  \\nalbuterol s...   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  Document 181: been studied. If treatment is to...   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  Document 184: Lopressor\\nPlacebo\\nHypotension ...   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  Document 114: CALCIUM CARBONATE\\n (UNII: H0G93...   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  Document 216: #\\nItem Code\\nPackage Descriptio...   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  Document 78: Select Azole Antifungals or Macro...   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  Document 361: Product: \\n50090-2980\\nNDC: \\n50...   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  Document 320: Suicidal Thoughts and Behaviors\\...   \n",
       "\n",
       "                                                                   conversation_history  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612                                                 []   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c                                                 []   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd                                                 []   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210                                                 []   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2                                                 []   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba                                                 []   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3                                                 []   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  [{'role': 'user', 'content': 'Patients prescri...   \n",
       "\n",
       "                                                                               metadata  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  {'question_type': 'simple', 'seed_document_id'...   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  {'question_type': 'complex', 'seed_document_id...   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  {'question_type': 'complex', 'seed_document_id...   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  {'question_type': 'distracting element', 'seed...   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  {'question_type': 'situational', 'seed_documen...   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  {'question_type': 'situational', 'seed_documen...   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  {'question_type': 'double', 'original_question...   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  {'question_type': 'conversational', 'seed_docu...   \n",
       "\n",
       "                                                                           agent_answer  \\\n",
       "id                                                                                        \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  The ALBUTEROL SULFATE inhalation solution is a...   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  The document highlights the following precauti...   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  Here are the adverse reactions reported during...   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  Based on the provided document, I can share th...   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  The active ingredient in the **Albuterol Sulfa...   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  Based on the provided context, here are key ri...   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  Here are the key instructions patients should ...   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  The provided document snippet lists pharmaceut...   \n",
       "\n",
       "                                      correctness  \\\n",
       "id                                                  \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612        False   \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c        False   \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd        False   \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210        False   \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2        False   \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba        False   \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3        False   \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3        False   \n",
       "\n",
       "                                                                     correctness_reason  \n",
       "id                                                                                       \n",
       "76e4e628-e8be-4675-a04e-1208c39eb612  The agent provided additional information abou...  \n",
       "3a0b5032-84e3-405d-a8c9-43d62cd79c3c  The agent provided additional information abou...  \n",
       "2e22dd3f-eae2-446f-a07b-5410126788cd  The agent provided some adverse reactions repo...  \n",
       "73e18ef5-254e-44e7-9171-26ca90d40210  The agent provided the inactive ingredients fo...  \n",
       "7cd4bf5b-e8b5-412d-9015-7fc4967b63d2  The agent stated that the strength of the Albu...  \n",
       "b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba  The agent provided detailed information about ...  \n",
       "92d517b2-54d4-44ce-a923-08c44e3c6ed3  The agent provided additional instructions for...  \n",
       "c940d678-3141-4420-b01d-6ab2179e11d3  The agent provided a general response about ph...  "
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.get_failures()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Failures saved to giskard_failures.xlsx\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Assuming `report.get_failures()` returns a list of dicts or objects\n",
    "failures = report.get_failures()\n",
    "\n",
    "# If it's already a list of dictionaries, this will work:\n",
    "df_failures = pd.DataFrame(failures)\n",
    "\n",
    "# Save to Excel\n",
    "df_failures.to_excel(\"giskard_failures.xlsx\", index=False)\n",
    "print(\"Failures saved to giskard_failures.xlsx\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
